Johnson & Johnson (JNJ) 10-Q 1 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Apr. 01, 2018	Apr. 26, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	JOHNSON & JOHNSON
Entity Central Index Key	200,406
Current Fiscal Year End Date	--12-30
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Apr. 1, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,682,149,964

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Apr. 01, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 14,639	$ 17,824
Marketable securities	565	472
Accounts receivable, trade, less allowances for doubtful accounts $281 (2017, $291)	14,166	13,490
Inventories (Note 2)	9,014	8,765
Prepaid expenses and other	2,641	2,537
Assets held for sale (Note 10)	1,743	0
Total current assets	42,768	43,088
Property, plant and equipment at cost	41,996	41,466
Less: accumulated depreciation	(24,956)	(24,461)
Property, plant and equipment, net	17,040	17,005
Intangible assets, net (Note 3)	52,365	53,228
Goodwill (Note 3)	31,149	31,906
Deferred taxes on income	8,785	7,105
Other assets	4,518	4,971
Total assets	156,625	157,303
Current liabilities:
Loans and notes payable	2,696	3,906
Accounts payable	6,443	7,310
Accrued liabilities	6,535	7,304
Accrued rebates, returns and promotions	7,956	7,210
Accrued compensation and employee related obligations	1,892	2,953
Accrued taxes on income	1,559	1,854
Total current liabilities	27,081	30,537
Long-term debt (Note 4)	29,837	30,675
Deferred taxes on income	8,057	8,368
Employee related obligations	10,066	10,074
Accrued Income Taxes, Noncurrent	9,453	8,472
Other liabilities	8,876	9,017
Total liabilities	93,370	97,143
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(12,608)	(13,199)
Retained earnings	104,339	101,793
Less: common stock held in treasury, at cost (437,654,000 and 437,318,000 shares)	31,596	31,554
Total shareholders’ equity	63,255	60,160
Total liabilities and shareholders' equity	$ 156,625	$ 157,303

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Apr. 01, 2018	Dec. 31, 2017
Current assets:
Allowances for doubtful accounts	$ 281	$ 291
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000,000	4,320,000,000
Common stock, shares issued	3,119,843,000	3,119,843,000
Treasury stock, shares	437,654,000	437,318,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Income Statement [Abstract]
Sales to customers (Note 9)	$ 20,009	$ 17,766
Sales to customers percent to sales	100.00%	100.00%
Cost of products sold	$ 6,614	$ 5,409
Cost of products sold percent to sales	33.10%	30.40%
Gross profit	$ 13,395	$ 12,357
Gross profit percent to sales	66.90%	69.60%
Selling, marketing and administrative expenses	$ 5,263	$ 4,763
Selling marketing and administrative expenses percent to sales	26.30%	26.80%
Research and development expense	$ 2,404	$ 2,070
Research and development expense percent to sales	12.00%	11.70%
Interest income	$ (114)	$ (121)
Interest income percent to sales	(0.60%)	(0.70%)
Interest expense, net of portion capitalized	$ 259	$ 204
Interest expense, net of portion capitalized percent to sales	1.30%	1.20%
Other (income) expense, net	$ 60	$ (219)
Other (income) expense, net percent to sales	0.30%	(1.30%)
Restructuring (Note 12)	$ 42	$ 85
Restructuring charge percent to sales	0.20%	0.50%
Earnings before provision for taxes on income	$ 5,481	$ 5,575
Earnings before provision for taxes on income percent to sales	27.40%	31.40%
Provision for taxes on income (Note 5)	$ 1,114	$ 1,153
Provision for taxes on income perent to sales	5.60%	6.50%
NET EARNINGS	$ 4,367	$ 4,422
Net earnings percent to sales	21.80%	24.90%
NET EARNINGS PER SHARE (Note 8)
Basic (per share)	$ 1.63	$ 1.63
Diluted (per share)	1.60	1.61
CASH DIVIDENDS PER SHARE	$ 0.84	$ 0.80
AVG. SHARES OUTSTANDING
Basic (shares)	2,682.2	2,706.6
Diluted (shares)	2,731.9	2,754.5

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Statement of Comprehensive Income [Abstract]
Net earnings	$ 4,367	$ 4,422
Other comprehensive income (loss), net of tax
Foreign currency translation	623	395
Securities:(1)
Unrealized holding gain (loss) arising during period	0	89
Reclassifications to earnings	0	(179)
Net change	0	(90)
Employee benefit plans:
Prior service cost amortization during period	(6)	(4)
Gain (loss) amortization during period	192	123
Net change	186	119
Derivatives & hedges:
Unrealized gain (loss) arising during period	(164)	(224)
Reclassifications to earnings	178	179
Net change	14	(45)
Other comprehensive income (loss)	823	379
Comprehensive income	$ 5,190	$ 4,801

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Consolidated Statement of Comprehensive Income [Abstract]
Foreign Currency Translation	$ 163
Securities	0	$ (48)
Employee Benefits	(52)	(60)
Derivatives & Hedges	$ 4	$ (24)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 4,367	$ 4,422
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	1,746	912
Stock based compensation	268	229
Asset write-downs	0	37
Deferred tax provision	44	(27)
Accounts receivable allowances	(20)	(13)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(479)	(96)
Increase in inventories	(322)	(368)
Decrease in accounts payable and accrued liabilities	(1,686)	(2,030)
Increase in other current and non-current assets	(907)	(424)
Increase in other current and non-current liabilities	595	271
NET CASH FLOWS FROM OPERATING ACTIVITIES	3,606	2,913
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(658)	(560)
Proceeds from the disposal of assets/businesses, net	20	31
Acquisitions, net of cash acquired	(82)	(4,852)
Purchases of investments	(548)	(4,550)
Sales of investments	341	8,994
Other	2	1
NET CASH USED BY INVESTING ACTIVITIES	(925)	(936)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(2,253)	(2,171)
Repurchase of common stock	(1,444)	(3,342)
Proceeds from short-term debt	26	719
Retirement of short-term debt	(2,484)	(195)
Proceeds from long-term debt, net of issuance costs	2	4,464
Retirement of long-term debt	(8)	(2)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	66	402
Other	125	(25)
NET CASH USED BY FINANCING ACTIVITIES	(5,970)	(150)
Effect of exchange rate changes on cash and cash equivalents	104	110
(Decrease)/Increase in cash and cash equivalents	(3,185)	1,937
Cash and Cash equivalents, beginning of period	17,824	18,972
CASH AND CASH EQUIVALENTS, END OF PERIOD	14,639	20,909
Acquisitions
Fair value of assets acquired	119	5,250
Fair value of liabilities assumed and noncontrolling interests	(37)	(398)
Net cash paid for acquisitions	$ 82	$ 4,852

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Apr. 01, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 . The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. New Accounting Standards Recently Adopted Accounting Standards ASU 2014-09 : Revenue from Contracts with Customers On January 1, 2018, the Company adopted the new accounting standard, ASC 606, Revenue from Contracts with Customers and all the related amendments (new revenue standard) to all contracts using the modified retrospective method. The cumulative effect of initially applying the new standard was recognized as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The adoption of the new revenue standard has not had a material impact to either reported Sales to customers or Net earnings. Additionally, the Company will continue to recognize revenue from product sales as goods are shipped or delivered to the customer, as control of goods occurs at the same time. In accordance with the new standard requirements, the disclosure of the impact of adoption on the Company's Consolidated Statement of Earnings and Balance Sheet was as follows: Statement of Earnings - For the fiscal three months ended April 1, 2018 (Dollars in millions) As Reported Effect of change Balance without adoption of ASC 606 Sales to customers $ 20,009 (29 ) 19,980 Net earnings 4,367 (25 ) 4,342 Balance Sheet - As of April 1, 2018 As Reported Effect of change Balance without adoption of ASC 606 Assets 156,625 19 156,644 Liabilities 93,370 (3 ) 93,367 Equity $ 63,255 22 63,277 The Company made a cumulative effect adjustment to the 2018 opening balance of retained earnings upon adoption of ASU 2014-09, which decreased beginning retained earnings by $47 million . As part of the adoption of ASC 606 see Note 9 to the Consolidated Financial Statements for further disaggregation of revenue. The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted as variable consideration and recorded as a reduction in sales. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates, which include the Medicaid rebate provision, are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal reporting years 2017, 2016 and 2015. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. The Company also earns service revenue for co-promotion of certain products, which is included in sales to customers. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. ASU 2016-01 : Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities The Company adopted this standard as of the beginning of the fiscal year 2018 on a modified retrospective basis. The amendments in this update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities to be measured at fair value with changes in the fair value recognized through net earnings. The standard amends financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. The Company made a cumulative effect adjustment to the opening balance of retained earnings upon adoption of ASU 2016-01 that increased retained earnings by $232 million net of tax and decreased accumulated other comprehensive income for previously unrealized gains from equity investments. For additional details see Note 4 to the Consolidated Financial Statements. ASU 2016-16 : Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory The Company adopted this standard as of the beginning of the fiscal year 2018. This update removes the current exception in U.S. GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. The Company recorded net adjustments to deferred taxes of approximately $2.0 billion , a decrease to Other Assets of approximately $0.7 billion and an increase to retained earnings of approximately $1.3 billion . The Company does not expect the adoption of this standard to have a significant impact on the Company's 2018 financial results. ASU 2017-01 : Clarifying the Definition of a Business The Company adopted this standard as of the beginning of the fiscal year 2018. This update narrows the definition of a business by providing a screen to determine when an integrated set of assets and activities is not a business. The screen specifies that an integrated set of assets and activities is not a business if substantially all of the fair value of the gross assets acquired or disposed of is concentrated in a single or a group of similar identifiable assets. This update was applied prospectively. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2017-07 : Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost The Company adopted this standard as of the beginning of the fiscal year 2018. This update requires that an employer disaggregate the service cost component from the other components of net periodic benefit cost (“NPBC”). In addition, only the service cost component will be eligible for capitalization. The amendments in this update are required to be applied retrospectively for the presentation of the service cost component and the other components of NPBC in the Consolidated Statement of Earnings and prospectively, on and after the adoption date, for the capitalization of the service cost component of NPBC in assets. As required by the transition provisions of this update, the Company made the following reclassifications to the 2017 fiscal first quarter Consolidated Statement of Earnings to retroactively apply classification of the service cost component and the other components of NPBC: (Dollars In millions) Increase (Decrease) to Net Expense Cost of products sold $ 23 Selling, marketing and administrative expenses 26 Research and development expense 10 Other (income) expense, net (59 ) Earnings before provision for taxes on income $ — The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of the new accounting standards mentioned above: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47 ) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers 1,311 Total $ 1,496 Recently Issued Accounting Standards Not Adopted as of April 1, 2018 ASU 2018-02 : Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income This update allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017. This update will be effective for the Company for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect this standard to have a material impact on the Company's consolidated financial statements. ASU 2017-12 : Targeted Improvements to Accounting for Hedging Activities This update makes more financial and nonfinancial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. This update will be effective for the Company for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is planning to early adopt this standard in the fiscal second quarter of 2018 and does not expect the adoption to have a material impact on its financial statements. ASU 2016-02 : Leases This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current generally accepted accounting principles. This update will be effective for the Company for all annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company anticipates that most of its operating leases will result in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheets, however it does not expect the standard to have a material impact on the financial position. The actual impact will depend on the Company's lease portfolio at the time of adoption. The Company continues to assess all implications of the standard and related financial disclosures.

Inventories

Inventories	3 Months Ended
	Apr. 01, 2018
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) April 1, 2018 December 31, 2017 Raw materials and supplies $ 1,200 1,140 Goods in process 2,339 2,317 Finished goods 5,475 5,308 Total inventories (1) $ 9,014 8,765 (1) Net of approximately $0.1 billion classified as assets held for sale on the Consolidated Balance Sheet, related to the divestiture of the LifeScan business which was pending as of April 1, 2018

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Apr. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2017 . Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) April 1, 2018 December 31, 2017 Intangible assets with definite lives: Patents and trademarks — gross $ 35,980 36,427 Less accumulated amortization 7,594 7,223 Patents and trademarks — net (1) 28,386 29,204 Customer relationships and other intangibles — gross 21,141 20,204 Less accumulated amortization 7,748 7,463 Customer relationships and other intangibles — net 13,393 12,741 Intangible assets with indefinite lives: Trademarks 7,113 7,082 Purchased in-process research and development 3,473 4,201 Total intangible assets with indefinite lives 10,586 11,283 Total intangible assets — net $ 52,365 53,228 (1) Net of approximately $0.6 billion classified as assets held for sale on the Consolidated Balance Sheet. $0.5 billion is related to the divestiture of Valchlor and $0.1 billion is related to the divestiture of the LifeScan business, both of which were pending as of April 1, 2018. Goodwill as of April 1, 2018 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at December 31, 2017 $ 8,875 9,109 13,922 31,906 Goodwill, related to acquisitions — — 53 53 Goodwill, related to divestitures — — — — Currency translation/Other 24 147 (981 ) (1) (810 ) Goodwill, net at April 1, 2018 $ 8,899 9,256 12,994 31,149 (1) Net of approximately $1.0 billion classified as assets held for sale on the Consolidated Balance Sheet, related to the divestiture of the LifeScan business which was pending as of April 1, 2018. The weighted average amortization periods for patents and trademarks and customer relationships and other intangible assets are 11 years and 22 years, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $0.3 billion for the fiscal three months ended April 1, 2018 and April 2, 2017 , respectively. The estimated amortization expense for the five succeeding years approximates $4.4 billion , before tax, per year. Intangible asset write-downs are included in Other (income) expense, net. See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Apr. 01, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. The Company also uses equity collar contracts to manage exposure to market risk associated with certain equity investments. All three types of derivatives are designated as cash flow hedges. The Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. During the fiscal second quarter of 2017, the Company entered into credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April 1, 2018 , the total amount of collateral paid under the credit support agreements amounted to $32 million , net. For equity collar contracts, the Company pledged the underlying hedged marketable equity securities to the counter-party as collateral. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April 1, 2018 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $35.3 billion , $2.3 billion and $1.1 billion , respectively. As of December 31, 2017, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $34.5 billion , $2.3 billion and $1.1 billion , respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in Other (income) expense, net for forward foreign exchange contracts, cross currency interest rate swaps, net investment hedges and equity collar contracts. For interest rate swaps designated as fair value hedges, hedge ineffectiveness, if any, is included in current period earnings within interest expense. For the current reporting period, hedge ineffectiveness associated with interest rate swaps was not material. During the fiscal second quarter of 2016, the Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. The change in the carrying value due to remeasurement of these Euro notes resulted in a $150 million unrealized pretax loss for the fiscal first quarter of April 1, 2018 reflected in foreign currency translation adjustment, within the Consolidated Statements of Comprehensive Income. The change in the carrying value due to remeasurement of these Euro notes resulted in a cumulative $372 million unrealized pretax loss from hedge inception through the fiscal first quarter of 2018, reflected in foreign currency translation adjustment, within the Consolidated Statements of Comprehensive Income. As of April 1, 2018 , the balance of deferred net gains on derivatives included in accumulated other comprehensive income was $84 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal first quarters in 2018 and 2017 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal First Quarters Ended Cash Flow Hedges By Income Statement Caption April 1, 2018 April 2, 2017 April 1, 2018 April 2, 2017 April 1, 2018 April 2, 2017 Sales to customers (3) $ 31 (13 ) 29 (33 ) — — Cost of products sold (3) 3 (97 ) 2 (31 ) 12 (17 ) Research and development expense (3) (237 ) (109 ) (238 ) (102 ) — 5 Interest (income)/Interest expense, net (4) 57 28 40 22 — — Other (income) expense, net (3) (5) (18 ) (33 ) (11 ) (35 ) 5 1 Total $ (164 ) (224 ) (178 ) (179 ) 17 (11 ) All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps (5) Includes equity collar contracts. The equity collar contracts expired in December of 2017 For the fiscal first quarters ended April 1, 2018 and April 2, 2017 , a loss of $19 million and $29 million , respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments. The Company adopted ASU 2016-01: Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities as of the beginning of the fiscal year 2018. This ASU amends prior guidance to classify equity investments with readily determinable market values into different categories (that is, trading or available-for-sale) and require equity investments to be measured at fair value with changes in fair value recognized through net earnings. The Company made a cumulative effect adjustment to the opening balance of retained earnings upon adoption of ASU 2016-01 which increased retained earnings by $232 million , net of tax, and decreased accumulated other comprehensive income for previously net unrealized gains from equity investments. The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments for the fiscal first quarter of 2018: (Dollars in Millions) December 31, 2017 April 1, 2018 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 751 (27 ) 7 731 731 Equity Investments without readily determinable value $ 510 (20 ) 83 573 573 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, $20 million of the changes in fair value reflected in net income that were the result of impairments. There were no changes related to adjustments due to changes in observable prices. For the fiscal first quarter ended April 2, 2017, changes in fair value reflected within other comprehensive income due to previously unrealized gains on equity investments with readily determinable fair values net of tax was a net gain of $349 million Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e. forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of April 1, 2018 and December 31, 2017 were as follows: April 1, 2018 December 31, 2017 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) (8) $ — 351 — 351 342 Interest rate contracts (2)(4) — 3 — 3 7 Total — 354 — 354 349 Liabilities: Forward foreign exchange contracts (7) (9) — 269 — 269 314 Interest rate contracts (3)(4)(7) (10) — 19 — 19 15 Total — 288 — 288 329 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 25 — 25 38 Liabilities: Forward foreign exchange contracts — 53 — 53 38 Other Investments: Equity investments (5) 731 — — 731 751 Debt securities (6) $ — 2,967 — 2,967 5,310 (1) 2017 assets and liabilities are all classified as Level 2 with the exception of equity investments of $751 million , which are classified as Level 1. (2) Includes $2 million and $7 million of non-current other assets for April 1, 2018 and December 31, 2017, respectively. (3) Includes $14 million and $9 million of non-current other liabilities for April 1, 2018 and December 31, 2017, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. The carrying amount of the equity investments were $731 million and $751 million as of April 1, 2018 and December 31, 2017, respectively. (6) Classified as cash equivalents and current marketable securities. (7) Includes collateral exchanged on the credit support agreements on derivatives (8) Forward foreign exchange contracts excluding CSA were $478 million and $418 million for April 1, 2018 and December 31, 2017, respectively. (9) Forward foreign exchange contracts excluding CSA were $364 million and $402 million for April 1, 2018 and December 31, 2017, respectively. (10) Interest rate contracts excluding CSA were $83 million and $165 million for April 1, 2018 and December 31, 2017, respectively. The Company's cash, cash equivalents and current marketable securities as of April 1, 2018 comprised: April 1, 2018 (Dollars in Millions) Carrying Amount Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,656 2,656 2,656 Other Sovereign Securities (1) 529 529 529 U.S. Reverse repurchase agreements 2,682 2,682 2,682 Other Reverse repurchase agreements 398 398 398 Corporate debt securities (1) 1,869 1,869 1,864 5 Money market funds 2,944 2,944 2,944 Time deposits (1) 1,159 1,159 1,159 Subtotal 12,237 12,237 12,232 5 Gov't securities 2,705 2,705 2,370 335 Other Sovereign Securities 2 2 — 2 Corporate debt securities 260 260 37 223 Subtotal available for sale debt (2) $ 2,967 2,967 2,407 560 Total cash, cash equivalents and current marketable securities 14,639 565 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. In the fiscal first quarter ended April 1, 2018 and the fiscal year ended December 31, 2017 the carrying amount was the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as cash equivalents and current marketable securities. The contractual maturities of the available for sale securities at April 1, 2018 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 2,887 2,887 Due after one year through five years 80 80 Due after five years through ten years — — Total debt securities $ 2,967 2,967 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April 1, 2018 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 2,696 2,696 Non-Current Debt 4.75% Notes due 2019 (1B Euro 1.2323) 1,230 1,330 1.875% Notes due 2019 495 492 3% Zero Coupon Convertible Subordinated Debentures due in 2020 52 92 1.950% Notes due 2020 499 492 2.95% Debentures due 2020 547 553 3.55% Notes due 2021 448 461 2.45% Notes due 2021 349 347 1.65% Notes due 2021 998 973 0.250% Notes due 2022 (1B Euro 1.2323) 1,229 1,236 2.25% Notes due 2022 995 975 6.73% Debentures due 2023 250 298 3.375% Notes due 2023 806 827 2.05% Notes due 2023 498 478 0.650% Notes due 2024 (750MM Euro 1.2323) 920 926 5.50% Notes due 2024 (500 MM GBP 1.4063) 697 865 2.625% Notes due 2025 747 722 2.45% Notes due 2026 1,991 1,877 2.95% Notes due 2027 995 968 2.90% Notes due 2028 1,492 1,443 1.150% Notes due 2028 (750MM Euro 1.2323) 916 923 6.95% Notes due 2029 296 397 4.95% Debentures due 2033 498 580 4.375% Notes due 2033 856 938 1.650% Notes due 2035 (1.5B Euro 1.2323) 1,830 1,907 3.55% Notes due 2036 987 978 5.95% Notes due 2037 991 1,289 3.625% Notes due 2037 1,486 1,479 3.40% Notes due 2038 990 961 5.85% Debentures due 2038 696 908 4.50% Debentures due 2040 538 604 4.85% Notes due 2041 296 340 4.50% Notes due 2043 495 545 3.70% Notes due 2046 1,971 1,966 3.75% Notes due 2047 991 991 3.50% Notes due 2048 742 716 Other 20 20 Total Non-Current Debt $ 29,837 30,897 The weighted average effective interest rate on non-current debt is 3.19% . The excess of the estimated fair value over the carrying value of debt was $2.0 billion at December 31, 2017. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	3 Months Ended
	Apr. 01, 2018
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal three months of 2018 and 2017 were 20.3% and 20.7% , respectively. The U.S. Tax Cuts and Jobs Act (TCJA) was enacted into law effective January 1, 2018. This law reduces the U.S. statutory corporate tax rate from 35% to 21% , eliminates or reduces certain corporate income tax deductions and introduces a tax on global intangible low-taxed income (GILTI). In December 2017, the Company recorded a provisional tax cost of $13.0 billion related to the enactment of the TCJA. Under the guidance in SEC Staff Accounting Bulletin 118 (SAB 118), the provisional amount was a reasonable estimate based on the most recent information and guidance available related to the calculation of the tax liability and the impact to its deferred tax assets and liabilities, including those recorded for foreign local and withholding taxes as of the 2017 assessment date of January 18, 2018. As noted below, the Company made adjustments in the first quarter of 2018. All amounts recorded remain provisional and may require further adjustments and changes to the Company’s estimates as new guidance is made available. The estimate is subject to the finalization of management’s analysis related to certain matters, such as developing interpretations of the provisions of the TCJA, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of tax returns. Revisions to the provisional charge may be material to the Company's future financial results. See Note 8 to the Consolidated Financial Statements in the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 for further details on the TCJA and SAB 118. The Company completed its acquisition of AMO in the first fiscal quarter of 2017, and incurred incremental tax costs that were discretely recorded in the first quarter of 2017, which increased the effective tax rate by 3.8% for the first three months of 2017 compared to the same period in 2018. Additionally, in 2018 the Company had more income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2017. Remeasurement of deferred tax liabilities and assets recorded for the foreign withholding taxes and related U.S. foreign tax credits, respectively, increased the Company’s effective tax rate in 2018 by approximately 1.4% due to changes in the foreign currency exchange rates. Tax benefits received from stock-based compensation during the fiscal three months of 2018 and 2017, reduced the effective tax rate by 2.2% and 3.6% , respectively. The reduction of the U.S. statutory corporate tax rate, offset by the elimination of the corporate income tax deductions, measurement period adjustments (1) and the GILTI tax (2) , decreased the Company’s worldwide effective rate as compared to the same period of the prior year. As previously disclosed, the Company has elected to provisionally treat the GILTI tax as a period expense, pending further analysis by management of this new tax provision. (1) The following adjustments were made to the provisional tax amounts in the first fiscal quarter of 2018 due to issued Treasury guidance and revisions to the Company’s estimates since the assessment date: • $0.2 billion increase to the transition tax on previously undistributed foreign earnings as of December 31, 2017 due to U.S. Treasury Department’s issuance of Notice 2018-13 on January 19, 2018 • $0.3 billion decrease to the deferred tax liability for foreign local taxes, partially offset by a decrease of $0.1 billion in deferred tax assets for U.S. foreign tax credits due to updated estimates from the amounts recorded in 2017. These measurement period adjustments decreased the Company’s effective tax rate by approximately 0.5% in the first fiscal quarter of 2018 as compared to the same period of the prior year. (2) The impact of GILTI on the first quarter effective tax rate was an increase of 2.6% . As of April 1, 2018 , the Company had approximately $3.2 billion of liabilities from unrecognized tax benefits. The Company believes it is possible that audits may be completed by tax authorities in some jurisdictions over the next twelve months. The Company is not able to provide a reasonably reliable estimate of the timing of any future tax payments relating to uncertain tax positions.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	3 Months Ended
	Apr. 01, 2018
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefits	PENSIONS AND OTHER BENEFIT PLANS Components of Net Periodic Benefit Cost Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal first quarters of 2018 and 2017 include the following components: Fiscal First Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) April 1, 2018 April 2, 2017 April 1, 2018 April 2, 2017 Service cost $ 309 251 67 61 Interest cost 252 230 37 39 Expected return on plan assets (560 ) (505 ) (2 ) (2 ) Amortization of prior service cost/(credit) 1 — (8 ) (7 ) Recognized actuarial losses 215 152 30 34 Curtailments and settlements (2 ) — — — Net periodic benefit cost $ 215 128 124 125 As per the adoption of ASU 2017-07, the service cost component of net periodic benefit cost was presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company Contributions For the fiscal three months ended April 1, 2018 , the Company contributed $18 million and $9 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Apr. 01, 2018
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 31, 2017 $ (7,351 ) 232 (6,150 ) 70 (13,199 ) Net change 623 — 186 14 823 Cumulative adjustment to retained earnings (232 ) (1) (232 ) April 1, 2018 $ (6,728 ) — (5,964 ) 84 (12,608 ) (1) See Note 1 to the Consolidated Financial Statements for additional details on the adoption of ASU 2016-01 Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Apr. 01, 2018
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal first quarters ended April 1, 2018 and April 2, 2017 : Fiscal First Quarters Ended (Shares in Millions) April 1, 2018 April 2, 2017 Basic net earnings per share $ 1.63 1.63 Average shares outstanding — basic 2,682.2 2,706.6 Potential shares exercisable under stock option plans 139.5 141.2 Less: shares which could be repurchased under treasury stock method (90.6 ) (94.6 ) Convertible debt shares 0.8 1.3 Average shares outstanding — diluted 2,731.9 2,754.5 Diluted net earnings per share $ 1.60 1.61 The diluted net earnings per share calculation for both the fiscal first quarters ended April 1, 2018 and April 2, 2017 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for both the fiscal first quarters ended April 1, 2018 and April 2, 2017 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive.

Segments of Business and Geogra

Segments of Business and Geographic Areas	3 Months Ended
	Apr. 01, 2018
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal First Quarters Ended (Dollars in Millions) April 1, April 2, Percent Change CONSUMER Baby Care U.S. $ 97 113 (14.2 )% International 360 342 5.3 Worldwide 457 455 0.4 Beauty U.S. 611 567 7.8 International 473 414 14.3 Worldwide 1,084 981 10.5 Oral Care U.S. 157 156 0.6 International 222 206 7.8 Worldwide 379 362 4.7 OTC U.S. 465 477 (2.5 ) International 607 536 13.2 Worldwide 1,072 1,013 5.8 Women's Health U.S. 3 3 0.0 International 240 239 0.4 Worldwide 243 242 0.4 Wound Care/Other U.S. 103 98 5.1 International 60 77 (22.1 ) Worldwide 163 175 (6.9 ) TOTAL CONSUMER U.S. 1,436 1,414 1.6 International 1,962 1,814 8.2 Worldwide 3,398 3,228 5.3 PHARMACEUTICAL Immunology U.S. 2,000 2,123 (5.8 ) International 1,042 807 29.1 Worldwide 3,042 2,930 3.8 REMICADE ® U.S. 916 1,182 (22.5 ) U.S. Exports 142 165 (13.9 ) International 331 325 1.8 Worldwide 1,389 1,672 (16.9 ) SIMPONI / SIMPONI ARIA ® U.S. 224 229 (2.2 ) International 294 199 47.7 Worldwide 518 428 21.0 STELARA ® U.S. 652 547 19.2 International 409 276 48.2 Worldwide 1,061 823 28.9 OTHER IMMUNOLOGY U.S. 66 — * International 8 7 14.3 Worldwide 74 7 * Infectious Diseases U.S. 333 326 2.1 International 497 423 17.5 Worldwide 830 749 10.8 EDURANT ® / rilpivirine U.S. 14 12 16.7 International 196 137 43.1 Worldwide 210 149 40.9 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 273 259 5.4 International 205 171 19.9 Worldwide 478 430 11.2 OTHER INFECTIOUS DISEASES U.S. 46 55 (16.4 ) International 96 115 (16.5 ) Worldwide 142 170 (16.5 ) Neuroscience U.S. 624 664 (6.0 ) International 935 833 12.2 Worldwide 1,559 1,497 4.1 CONCERTA ® / Methylphenidate U.S. 66 108 (38.9 ) International 107 101 5.9 Worldwide 173 209 (17.2 ) INVEGA SUSTENNA ® / XEPLION ® / TRINZA ® / TREVICTA ® U.S. 400 372 7.5 International 296 232 27.6 Worldwide 696 604 15.2 RISPERDAL CONSTA ® U.S. 82 95 (13.7 ) International 114 112 1.8 Worldwide 196 207 (5.3 ) OTHER NEUROSCIENCE U.S. 76 89 (14.6 ) International 418 388 7.7 Worldwide 494 477 3.6 Oncology U.S. 933 664 40.5 International 1,378 930 48.2 Worldwide 2,311 1,594 45.0 DARZALEX ® U.S. 264 201 31.3 International 168 54 * Worldwide 432 255 69.4 IMBRUVICA ® U.S. 227 190 19.5 International 360 219 64.4 Worldwide 587 409 43.5 VELCADE ® U.S. — — — International 313 280 11.8 Worldwide 313 280 11.8 ZYTIGA ® U.S. 407 233 74.7 International 438 290 51.0 Worldwide 845 523 61.6 OTHER ONCOLOGY U.S. 35 40 (12.5 ) International 99 87 13.8 Worldwide 134 127 5.5 Pulmonary Hypertension U.S. 361 — * International 224 — * Worldwide 585 — * OPSUMIT ® U.S. 149 — * International 122 — * Worldwide 271 — * TRACLEER ® U.S. 68 — * International 72 — * Worldwide 140 — * UPTRAVI ® U.S. 124 — * International 16 — * Worldwide 140 — * OTHER U.S. 20 — * International 14 — * Worldwide 34 — * Cardiovascular / Metabolism / Other U.S. 1,103 1,095 0.7 International 414 380 8.9 Worldwide 1,517 1,475 2.8 XARELTO ® U.S. 578 513 12.7 International — — — Worldwide 578 513 12.7 INVOKANA ® / INVOKAMET ® U.S. 204 247 (17.4 ) International 44 37 18.9 Worldwide 248 284 (12.7 ) PROCRIT ® / EPREX ® U.S. 189 169 11.8 International 87 78 11.5 Worldwide 276 247 11.7 OTHER U.S. 132 166 (20.5 ) International 283 265 6.8 Worldwide 415 431 (3.7 ) TOTAL PHARMACEUTICAL U.S. 5,354 4,872 9.9 International 4,490 3,373 33.1 Worldwide 9,844 8,245 19.4 MEDICAL DEVICES Diabetes Care U.S. 117 154 (24.0 ) International 222 245 (9.4 ) Worldwide 339 399 (15.0 ) Diagnostics U.S. — — — International — 1 * Worldwide — 1 * Interventional Solutions U.S. 304 279 9.0 International 336 270 24.4 Worldwide 640 549 16.6 Orthopaedics U.S. 1,307 1,359 (3.8 ) International 943 916 2.9 Worldwide 2,250 2,275 (1.1 ) HIPS U.S. 209 209 0.0 International 154 143 7.7 Worldwide 363 352 3.1 KNEES U.S. 228 246 (7.3 ) International 159 152 4.6 Worldwide 387 398 (2.8 ) TRAUMA U.S. 407 391 4.1 International 289 251 15.1 Worldwide 696 642 8.4 SPINE & OTHER U.S. 463 513 (9.7 ) International 341 370 (7.8 ) Worldwide 804 883 (8.9 ) Surgery U.S. 993 995 (0.2 ) International 1,430 1,276 12.1 Worldwide 2,423 2,271 6.7 ADVANCED U.S. 393 392 0.3 International 573 485 18.1 Worldwide 966 877 10.1 GENERAL U.S. 423 423 0.0 International 704 651 8.1 Worldwide 1,127 1,074 4.9 SPECIALTY U.S. 177 180 (1.7 ) International 153 140 9.3 Worldwide 330 320 3.1 Vision Care U.S. 440 305 44.3 International 675 493 36.9 Worldwide 1,115 798 39.7 CONTACT LENSES / OTHER U.S. 309 256 20.7 International 498 427 16.6 Worldwide 807 683 18.2 SURGICAL U.S. 131 49 * International 177 66 * Worldwide 308 115 * TOTAL MEDICAL DEVICES U.S. 3,161 3,092 2.2 International 3,606 3,201 12.7 Worldwide 6,767 6,293 7.5 WORLDWIDE U.S. 9,951 9,378 6.1 International 10,058 8,388 19.9 Worldwide $ 20,009 17,766 12.6 % *Percentage greater than 100% or not meaningful EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal First Quarters Ended (Dollars in Millions) April 1, April 2, Percent Change Consumer (1) $ 548 596 (8.1 )% Pharmaceutical (2) 3,666 3,663 0.1 Medical Devices (3) 1,579 1,563 1.0 Segment earnings before provision for taxes 5,793 5,822 (0.5 ) Less: Expense not allocated to segments (4) 312 247 Worldwide income before tax $ 5,481 5,575 (1.7 )% (1) Includes amortization expense of $0.1 billion in the fiscal first quarters of 2018 and 2017. (2) Includes acquisition costs related to the Actelion acquisition of $0.1 billion in the fiscal first quarter of 2018. Includes a gain of $0.2 billion in the fiscal first quarter of 2017 related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. Includes amortization expense of $0.8 billion and $0.1 billion in the fiscal first quarters of 2018 and 2017, respectively. (3) Includes a restructuring related charge of $0.1 billion and $0.2 billion in the fiscal first quarters of 2018 and 2017, respectively. Includes amortization expense of $0.3 billion and $0.2 billion in the fiscal first quarters of 2018 and 2017, respectively. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal First Quarters Ended (Dollars in Millions) April 1, 2018 April 2, 2017 Percent Change United States $ 9,951 9,378 6.1 % Europe 4,797 3,858 24.3 Western Hemisphere, excluding U.S. 1,567 1,454 7.8 Asia-Pacific, Africa 3,694 3,076 20.1 Total $ 20,009 17,766 12.6 %

Business Combinations and Dives

Business Combinations and Divestitures	3 Months Ended
	Apr. 01, 2018
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES During the fiscal first quarter of 2018, the Company announced a binding offer from Platinum Equity, a private investment firm, to acquire its LifeScan business for approximately $2.1 billion , subject to customary adjustments. As of April 1, 2018, the assets held for sale on the Consolidated Balance Sheet were $0.1 billion of inventory, $0.2 billion of property, plant and equipment, $0.1 billion of intangible assets, net and $1.0 billion of goodwill. The Company will retain certain net liabilities associated with the LifeScan business. Additionally, during the fiscal first quarter of 2018, the Company announced the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery technologies, including a differentiated robotic-assisted surgery solution. On June 16, 2017, the Company completed the acquisition of Actelion Ltd through an all cash tender offer in Switzerland for $280 per share, amounting to $29.6 billion , net of cash acquired. As part of the transaction, immediately prior to the completion of the acquisition, Actelion spun out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. The shares of Idorsia are listed on the SIX Swiss Exchange (SIX). The Company currently holds 9.9% of the shares of Idorsia and has rights to an additional 22.1% of Idorsia equity through a convertible loan with a principal amount of approximately $0.5 billion . The convertible loan may be converted into Idorsia shares as follows: (i) up to an aggregate shareholding of 16% of Idorsia shares as a result of certain shareholders holding more than 20% of the issued Idorsia shares, and (ii) up to the balance of the remaining amount within 20 business days of the maturity date of the convertible loan, which has a ten year term, or if Idorsia undergoes a change of control transaction. The investment in Idorsia was recorded as a cost method investment in Other assets in the Company's consolidated Balance Sheet. The Company also exercised the option acquired on ACT-132577, a product within Idorsia being developed for resistant hypertension currently in phase 2 of clinical development. The Company has also entered into an agreement to provide Idorsia with a Swiss franc denominated credit facility of approximately $250 million . As of April 1, 2018, Idorsia has not made any draw-downs under the credit facility. Actelion has entered into a transitional services agreement with Idorsia. Actelion has established a leading franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH) that are highly complementary to the existing portfolio of the Company. The addition of Actelion’s specialty in-market medicines and late-stage products is consistent with the Company's efforts to grow in attractive and complementary therapeutic areas and serve patients with serious illnesses and significant unmet medical need. The Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. The following table presents the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date as well as the adjustments made up to April 1, 2018: (Dollars in Millions) June 16, 2017 April 1, 2018 Cash & Cash equivalents $ 469 469 Inventory (1) 759 759 Accounts Receivable 485 485 Other current assets 93 93 Property, plant and equipment 104 104 Goodwill 5,986 6,161 Intangible assets 25,010 25,010 Deferred Taxes 3 99 Other non-current assets 19 19 Total Assets Acquired 32,928 33,199 Current liabilities 531 956 Deferred Taxes 1,960 1,776 Other non-current liabilities 383 413 Total Liabilities Assumed 2,874 3,145 Net Assets Acquired $ 30,054 30,054 (1) Includes adjustment of $642 million to write-up the acquired inventory to its estimated fair value. Subsequent to the date of acquisition there was an adjustment of $0.2 billion to the deferred taxes and $0.4 billion to the current liabilities with the offset to goodwill. The assets acquired are recorded in the Pharmaceutical segment. The acquisition of Actelion resulted in approximately $6.2 billion of goodwill. The goodwill is primarily attributable to synergies expected to arise from the acquisition. The goodwill is not expected to be deductible for tax purposes. The purchase price allocation to the identifiable intangible assets is as follows: (Dollars in Millions) Intangible assets with definite lives: Patents and trademarks $ 24,230 Total amortizable intangibles 24,230 In-process research and development 780 Total intangible assets $ 25,010 The patents and trademarks acquired are comprised of developed technology with a weighted average life of 9 years and was primarily based on the patent life of the marketed products. The intangible assets with definite lives were assigned asset lives ranging from 4 to 10 years . As of April 1, 2018, patents and trademarks, net of a liability assumed, of $0.4 billion were classified as assets held for sale as they related to the pending divestiture of Valchlor, one of the acquired products. The in-process research and development intangible assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability adjusted cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 9% . The acquisition was accounted for using the acquisition method and, accordingly, the results of operations of Actelion were reported in the Company's financial statements beginning on June 16, 2017, the date of acquisition. The following table provides pro forma results of operations for the fiscal first quarter ended April 2, 2017 as if Actelion had been acquired as of January 4, 2016. The pro forma results include the effect of certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of Actelion. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future. Unaudited Pro forma Consolidated Results (Dollars in Millions Except Per Share Data) April 2, 2017 Net Sales $ 18,410 Net Earnings 4,099 Diluted Net Earnings per Common Share $ 1.49 In the fiscal first quarter of 2018, the Company recorded acquisition related costs, of approximately $0.1 billion before tax, which was recorded in Other (income)/expense and Cost of products sold. During the fiscal first quarter of 2017, the Company acquired Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, for $4.3 billion , net of cash acquired. The acquisition included ophthalmic products related to: cataract surgery, laser refractive surgery and consumer eye health. The net purchase price was primarily recorded as amortizable intangible assets for $2.3 billion and goodwill for $1.7 billion . The weighted average life of total amortizable intangibles, the majority being customer relationships, is approximately 14.4 years . The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not deductible for tax purposes. The intangible assets and goodwill amounts are based on the final purchase price allocation. The assets acquired were recorded in the Medical Devices segment. Additionally, during the fiscal first quarter of 2017, the Company completed the acquisitions of Torax Medical, Inc., a privately-held medical device company that manufactures and markets the LINX™ Reflux Management System for the surgical treatment of gastroesophageal reflux disease and Megadyne Medical Products, Inc., a privately-held medical device company that develops, manufactures and markets electrosurgical tools.

Legal Proceedings

Legal Proceedings	3 Months Ended
	Apr. 01, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of April 1, 2018 , the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors, including whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; or there are numerous parties involved. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; and INVOKANA ® . As of April 1, 2018 , in the U.S. there were approximately 2,000 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 10,200 with respect to the PINNACLE ® Acetabular Cup System; 54,000 with respect to pelvic meshes; 14,000 with respect to RISPERDAL ®; 26,300 with respect to XARELTO ®; 9,100 with respect to body powders containing talc; and 1,100 with respect to INVOKANA ® . In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, with more expected from the recent extension, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle two pending class actions, and the proposed settlements will be presented for approval to the Québec Superior Court and the Supreme Court of British Columbia respectively in May 2018. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States, primarily in the United Kingdom. In the United Kingdom, a trial was completed regarding common issues of liability and a decision is expected in the first half of 2018. The Company has established an accrual for defense costs only in connection with product liability litigation associated with the PINNACLE ® Acetabular Cup System. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Southern District of West Virginia. The Company has settled or otherwise resolved a majority of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and Belgium, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In Australia, a trial of class action issues is ongoing and a decision is expected in 2018. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established an accrual with respect to product liability litigation associated with RISPERDAL ® . Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson; and JPI's collaboration partner for XARELTO ® Bayer AG and certain of its affiliates. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania; and there are coordinated proceedings in Delaware, California and Missouri. Class action lawsuits also have been filed in Canada. The Company has established an accrual for defense costs only in connection with product liability litigation associated with XARELTO ® . Claims for personal injury have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSONS ® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. The Company has established an accrual for defense costs only in connection with product liability litigation associated with body powders containing talc. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts in Pennsylvania, California and New Jersey. Class action lawsuits have been filed in Canada. The Company has established an accrual with respect to product liability litigation associated with INVOKANA ® . INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVCI) in the United States District Court for the Eastern District of Texas alleging that JJVCI's manufacture and sale of its ACUVUE ® ADVANCE and ACUVUE OASYS ® Hydrogel Contact Lenses infringed Rembrandt’s United States Patent No. 5,712,327 and seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida, where a trial in May 2012 resulted in a verdict of non-infringement that was subsequently upheld on appeal. In July 2014, Rembrandt sought a new trial based on alleged new evidence, which the District Court denied. In April 2016, the Court of Appeals overturned that ruling and remanded the case to the District Court for a new trial. A new trial was held in August 2017, and the jury returned a verdict of non-infringement in favor of JJVCI. Rembrandt has appealed the verdict to the United States Court of Appeals for the Federal Circuit. In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that Cordis’s sales of the CYPHER ™ and CYPHER SELECT ™ stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Medinol is seeking damages and attorneys’ fees. After trial in January 2014, the District Court dismissed the case, finding Medinol unreasonably delayed bringing its claims (the laches defense). In September 2014, the District Court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol appealed the decision to the United States Court of Appeals for the Federal Circuit. In March 2017, the United States Supreme Court held that the laches defense is not available in patent cases and in April 2018, the United States Court of Appeals for the Federal Circuit remanded the case back to the District Court to reconsider Medinol's motion for a new trial. In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants. MedIdea alleges infringement of United States Patent Nos. 6,558,426 (’426); 8,273,132; 8,721,730 and 9,492,280 relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. In December 2017, DePuy Synthes Products, Inc. filed a Petition for Inter Partes Review with the United States Patent and Trademark Office, seeking to invalidate the ’426 patent. In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that United States Patent Nos. 6,585,735 (the ’735 patent); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (the ’284 patent), are either invalid or not infringed by Ethicon’s ENSEAL ® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG (collectively, Covidien) answered and counterclaimed, denying the allegations, asserting willful infringement of the ’735 patent, the ’284 patent and United States Patent Nos. 8,323,310; 9,084,608; 9,241,759 and 9,113,882, and seeking damages and an injunction. Covidien filed a motion for preliminary injunction, which was denied in October 2017. Trial is scheduled to begin in September 2019. In November 2017, Board of Regents, The University of Texas System and Tissuegen, Inc. filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® POS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 and 7,033,603 directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. A claim construction hearing is scheduled in October 2018. Pharmaceutical In April 2016, MorphoSys AG, a German biotech company, filed a patent infringement lawsuit against Janssen Biotech, Inc. (JBI), Genmab U.S. Inc. and Genmab A/S (collectively, Genmab) in the United States District Court for the District of Delaware. MorphoSys alleges that JBI’s manufacture and sale of DARZALEX ® (daratumumab) willfully infringes MorphoSys’ United States Patent Nos. 8,263,746, 9,200,061 and 9,785,590. MorphoSys is seeking money damages. JBI licenses patents and the commercial rights to DARZALEX ® from Genmab. Trial on liability and damages is scheduled to commence in February 2019. In August 2016, Sandoz Ltd and Hexal AG (collectively, Sandoz) filed a lawsuit in the English High Court against G.D. Searle LLC, a Pfizer company (Searle) and Janssen Sciences Ireland UC (JSI) alleging that Searle’s supplementary protection certificate SPC/GB07/038 (SPC), which is exclusively licensed to JSI, is invalid and should be revoked. Janssen-Cilag Limited sells PREZISTA ® (darunavir) in the United Kingdom pursuant to this license. In October 2016, Searle and JSI counterclaimed against Sandoz for threatened infringement of the SPC based on statements of its plans to launch generic darunavir in the United Kingdom. Sandoz admitted that its generic darunavir product would infringe the SPC if it is found valid. Searle and JSI are seeking an order enjoining Sandoz from marketing its generic darunavir before the expiration of the SPC. Following a trial in April 2017, the Court entered a decision holding that the SPC is valid and granting a final injunction. Sandoz has appealed the Court’s decision and the injunction will be stayed pending the appeal. In January 2018, the Court referred the issue on appeal to the Court of Justice for the European Union (CJEU) and stayed the proceedings pending the CJEU’s ruling on the issue. REMICADE ® Related Cases In August 2014, Celltrion Healthcare Co. Ltd. and Celltrion Inc. (collectively, Celltrion) filed an application with the United States Food and Drug Administration (FDA) for approval to make and sell its own infliximab biosimilar. In March 2015, Janssen Biotech, Inc. (JBI) filed a lawsuit in the United States District Court for the District of Massachusetts against Celltrion and Hospira Healthcare Corporation (Hospira), which has exclusive marketing rights for Celltrion's infliximab biosimilar in the United States, seeking, among other things, a declaratory judgment that their biosimilar product infringes or potentially infringes several JBI patents, including United States Patent No. 6,284,471 relating to REMICADE ® (infliximab) (the ’471 patent) and United States Patent No. 7,598,083 (the ’083 patent). In August 2016, the District Court granted both Celltrion's and Hospira's motions for summary judgment of invalidity of the ’471 patent. JBI appealed those decisions to the United States Court of Appeals for the Federal Circuit. In January 2018, the Federal Circuit dismissed the appeal as moot based on its affirmance of a decision by the USPTO’s Patent Trial and Appeal Board affirming invalidity of the ’471 patent. In June 2016, JBI filed two additional patent infringement lawsuits asserting the ’083 patent, one against Celltrion and Hospira in the United States District Court for the District of Massachusetts and the other against HyClone Laboratories, Inc., the manufacturer of the cell culture media that Celltrion uses to make its biosimilar product, in the United States District Court for the District of Utah. Although the ’083 patent is already asserted in the existing lawsuit against Celltrion, the additional lawsuit expands the claims to include the sale in the United States of Celltrion's biosimilar product manufactured with cell culture media made in the United States. This additional lawsuit against Celltrion has been consolidated with the existing lawsuit discussed above. Hospira has moved to dismiss all counts of the lawsuit related to the ’083 patent as to it. Trial is scheduled to begin in July 2018. The litigation against HyClone in Utah is stayed pending the outcome of the Massachusetts actions. The FDA approved the first infliximab biosimilar for sale in the United States in 2016, and a number of such products have been launched. Litigation Against Filers of Abbreviated New Drug Applications (ANDAs) The following summarizes lawsuits pending against generic companies that have filed Abbreviated New Drug Applications (ANDAs) with the FDA, or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson & Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of the applicable patents. In the event the subsidiaries are not successful in these actions, or the statutory 30-month stays of the ANDAs expire before the United States District Court rulings are obtained, the third-party companies involved will have the ability, upon approval of the FDA, to introduce generic versions of the products at issue to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The inter partes review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used by generic companies in conjunction with these ANDAs and lawsuits to challenge patents held by the Company’s subsidiaries. ZYTIGA ® In July 2015, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC (collectively, Janssen) and BTG International Ltd. (BTG) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies (and certain of their affiliates and/or suppliers) who filed ANDAs seeking approval to market a generic version of ZYTIGA ® 250mg before the expiration of United States Patent No. 8,822,438 (the ’438 patent). The generic companies currently include Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); Apotex Inc. and Apotex Corp. (collectively, Apotex); Citron Pharma LLC (Citron); Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, Dr. Reddy’s); Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan); Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. (collectively, Par); Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries, Inc. (collectively, Sun); Teva Pharmaceuticals USA, Inc. (Teva); Wockhardt Bio A.G.; Wockhardt USA LLC and Wockhardt Ltd. (collectively, Wockhardt); West-Ward Pharmaceutical Corp. (West-Ward) and Hikma Pharmaceuticals, LLC (Hikma). Janssen and BTG also initiated patent infringement lawsuits in the United States District Court for the District of New Jersey against Amerigen Pharmaceuticals Limited (Amerigen) in May 2016, and Glenmark Pharmaceuticals, Inc. (Glenmark) in June 2016, each of whom filed an ANDA seeking approval to market its generic version of ZYTIGA ® before the expiration of the ’438 patent. In August 2015, Janssen and BTG filed an additional jurisdictional protective lawsuit against the Mylan defendants in the United States District Court for the Northern District of West Virginia, which has been stayed. In August 2017, Janssen and BTG initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva, who filed an ANDA seeking approval to market a generic version of ZYTIGA ® 500mg before the expiration of the ’438 patent. In February 2018, Janssen and BTG filed a patent infringement lawsuit against MSN Pharmaceuticals, Inc. and MSN Laboratories Private Limited (collectively, MSN) based on its ANDA seeking approval for a generic version of ZYTIGA ® prior to the expiration of the ‘438 patent. In February 2018, the court heard oral arguments on a motion for summary judgment of non-infringement filed by certain defendants. The parties await a decision. If the decision is unfavorable, the stay could be lifted and a generic version of ZYTIGA ® could enter the market. Trial on the matter is scheduled for July 2018. In December 2017, Janssen and BTG entered into a settlement agreement with Glenmark. In January 2018, Janssen dismissed its lawsuit against Sun after it withdrew its ANDA. In April 2018, Janssen and BTG entered into a settlement agreement with Apotex. In each of the above lawsuits, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA ® before the expiration of the ’438 patent. Several generic companies including Amerigen, Argentum Pharmaceuticals LLC (Argentum), Mylan, Wockhardt, Actavis, Amneal, Dr. Reddy’s, Sun, Teva, West-Ward and Hikma filed Petitions for Inter Partes Review (IPR) with the USPTO, seeking to invalidate the ’438 patent. In January 2018, the USPTO issued decisions finding the '438 patent claims unpatentable, and Janssen has requested rehearing. The IPR decisions are not binding on the district court in the pending litigation. In October 2017, Janssen Inc. and Janssen Oncology, Inc. (collectively, Janssen) initiated two Notices of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva) and the Minister of Health in Canada in response to Teva's filing Abbreviated New Drug Submissions (ANDS) and seeking approval to market generic versions of ZYTIGA ® 250mg and ZYTIGA ® 500mg before the expiration of Canadian Patent No. 2,661,422. The federal court of Canada scheduled the Final Hearing for May 2019. In November 2017, Janssen initiated a Notice of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to Apotex’s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA ® before the expiration of Canadian Patent No. 2,661,422. The federal court of Canada scheduled the Final Hearing for April 2019. In each of these Notices of Application, Janssen is seeking an order prohibiting the Minister of Health from issuing a Notice of Compliance with respect to Teva's and Apotex's ANDS before the expiration of Janssen's patent. XARELTO ® B eginning in October 2015, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer Intellectual Property GmbH (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO ® before expiration of Bayer’s United States Patent Nos. 7,157,456, 7,585,860 and 7,592,339 relating to XARELTO ® . JPI is the exclusive sublicensee of the asserted patents. The following generic companies are named defendants: Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. (collectively, Aurobindo); Breckenridge Pharmaceutical, Inc. (Breckenridge); InvaGen Pharmaceuticals Inc. (InvaGen); Micro Labs USA Inc. and Micro Labs Ltd (collectively, Micro); Mylan Pharmaceuticals Inc. (Mylan); Prinston Pharmaceuticals, Inc.; Sigmapharm Laboratories, LLC (Sigmapharm); Torrent Pharmaceuticals, Limited and Torrent Pharma Inc. (collectively, Torrent). All defendants except Mylan and Sigmapharm have agreed to have their cases stayed and to be bound by the outcome of any final judgment rendered against any of the other defendants. Trial concluded in April 2018 and the parties are awaiting a decision. Beginning in April 2017, JPI and Bayer Intellectual Property GmbH and Bayer AG (collectively, Bayer AG) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO ® before expiration of Bayer AG’s United States Patent No. 9,539,218 (’218) relating to XARELTO ® . The following generic companies are named defendants: Alembic Pharmaceuticals Limited, Alembic Global Holding SA and Alembic Pharmaceuticals, Inc.; Aurobindo; Breckenridge; InvaGen; Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin); Micro; Mylan; Sigmapharm; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) and Torrent. Lupin has counterclaimed for a declaratory judgment of noninfringement and invalidity of United States Patent No. 9,415,053, but Lupin dismissed its counterclaims after it was provided a covenant not to sue on that patent. Aurobindo, Taro, Torrent, Micro and Breckenridge have agreed to have their cases stayed and to be bound by the outcome of any final judgment rendered against any of the other defendants. The ’218 cases have been consolidated for discovery and trial, and are currently set for trial in April 2019. In each of these lawsuits, JPI is seeking an order enjoining the defendants from marketing their generic versions of XARELTO ® before the expiration of the relevant patents. PREZISTA ® In November 2017, Janssen Inc. initiated Notices of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to Apotex’s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of PREZISTA ® before the expiration of Canadian Patent Nos. 2,485,834 and 2,336,160, which is owned by the United States and the Board of Trustees of the University of Illinois. Janssen is seeking an order prohibiting the Minister of Health from issuing a Notice of Compliance with respect to Apotex's ANDS before the expiration of the relevant patents. INVOKANA ® /INVOKAMET ® Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research & Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey, the United States District Court for the

Restructuring

Restructuring	3 Months Ended
	Apr. 01, 2018
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING In the first quarter of 2016, the Company announced restructuring actions in its Medical Devices segment to better serve the needs of patients and customers in today’s evolving healthcare marketplace. The Company is undertaking actions to strengthen its go-to-market model, accelerate the pace of innovation, further prioritize key platforms and geographies, and streamline operations while maintaining high quality standards. The Company estimates that, in connection with its plans, it will record pre-tax restructuring related charges of approximately $2.4 billion . In the fiscal first quarter of 2018, the Company recorded a pre-tax charge of $107 million , of which $6 million was included in cost of products sold and $59 million was included in other (income) expense. See the following table for additional details. Total project costs of $2.1 billion have been recorded since the restructuring was announced. Additionally, as part of the plan, the Company expects that the restructuring actions will result in position eliminations of approximately 5 percent of the Medical Devices segment’s global workforce. Approximately 2,500 positions have been eliminated of which 1,800 received separation payments since the restructuring announcement. Subsequent to the fiscal first quarter, the Company announced plans on April 17, 2018, to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Company expects the Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion , over the 4 to 5 year period of this activity. The Company estimates that approximately 70% of the cumulative pre-tax costs will result in cash outlays. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance related reserves and the associated spending under these restructuring programs through the fiscal three months of 2018: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, December 31, 2017 $ 229 — 38 267 Current year activity: Charges — 5 102 107 Cash payments (16 ) — (122 ) (138 ) Settled non cash — (5 ) — (5 ) Accrual adjustment — — — — Reserve balance, April 1, 2018* $ 213 — 18 231 *Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses. The Company expects that the Medical Devices restructuring program will be completed by the end of fiscal year 2018 with certain projects and severance charges continuing beyond that date. The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments has extended due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the recently announced Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	3 Months Ended
	Apr. 01, 2018
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as cash equivalents and current marketable securities.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Apr. 01, 2018
Accounting Policies [Abstract]
Schedule of New Accounting Pronouncements	As required by the transition provisions of this update, the Company made the following reclassifications to the 2017 fiscal first quarter Consolidated Statement of Earnings to retroactively apply classification of the service cost component and the other components of NPBC: (Dollars In millions) Increase (Decrease) to Net Expense Cost of products sold $ 23 Selling, marketing and administrative expenses 26 Research and development expense 10 Other (income) expense, net (59 ) Earnings before provision for taxes on income $ — The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of the new accounting standards mentioned above: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47 ) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers 1,311 Total $ 1,496 In accordance with the new standard requirements, the disclosure of the impact of adoption on the Company's Consolidated Statement of Earnings and Balance Sheet was as follows: Statement of Earnings - For the fiscal three months ended April 1, 2018 (Dollars in millions) As Reported Effect of change Balance without adoption of ASC 606 Sales to customers $ 20,009 (29 ) 19,980 Net earnings 4,367 (25 ) 4,342 Balance Sheet - As of April 1, 2018 As Reported Effect of change Balance without adoption of ASC 606 Assets 156,625 19 156,644 Liabilities 93,370 (3 ) 93,367 Equity $ 63,255 22 63,277

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Apr. 01, 2018
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) April 1, 2018 December 31, 2017 Raw materials and supplies $ 1,200 1,140 Goods in process 2,339 2,317 Finished goods 5,475 5,308 Total inventories (1) $ 9,014 8,765

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Apr. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) April 1, 2018 December 31, 2017 Intangible assets with definite lives: Patents and trademarks — gross $ 35,980 36,427 Less accumulated amortization 7,594 7,223 Patents and trademarks — net (1) 28,386 29,204 Customer relationships and other intangibles — gross 21,141 20,204 Less accumulated amortization 7,748 7,463 Customer relationships and other intangibles — net 13,393 12,741 Intangible assets with indefinite lives: Trademarks 7,113 7,082 Purchased in-process research and development 3,473 4,201 Total intangible assets with indefinite lives 10,586 11,283 Total intangible assets — net $ 52,365 53,228 (1) Net of approximately $0.6 billion classified as assets held for sale on the Consolidated Balance Sheet. $0.5 billion is related to the divestiture of Valchlor and $0.1 billion is related to the divestiture of the LifeScan business, both of which were pending as of April 1, 2018.
Goodwill	Goodwill as of April 1, 2018 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at December 31, 2017 $ 8,875 9,109 13,922 31,906 Goodwill, related to acquisitions — — 53 53 Goodwill, related to divestitures — — — — Currency translation/Other 24 147 (981 ) (1) (810 ) Goodwill, net at April 1, 2018 $ 8,899 9,256 12,994 31,149 (1) Net of approximately $1.0 billion classified as assets held for sale on the Consolidated Balance Sheet, related to the divestiture of the LifeScan business which was pending as of April 1, 2018.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 01, 2018
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal first quarters in 2018 and 2017 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal First Quarters Ended Cash Flow Hedges By Income Statement Caption April 1, 2018 April 2, 2017 April 1, 2018 April 2, 2017 April 1, 2018 April 2, 2017 Sales to customers (3) $ 31 (13 ) 29 (33 ) — — Cost of products sold (3) 3 (97 ) 2 (31 ) 12 (17 ) Research and development expense (3) (237 ) (109 ) (238 ) (102 ) — 5 Interest (income)/Interest expense, net (4) 57 28 40 22 — — Other (income) expense, net (3) (5) (18 ) (33 ) (11 ) (35 ) 5 1 Total $ (164 ) (224 ) (178 ) (179 ) 17 (11 ) All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps (5) Includes equity collar contracts. The equity collar contracts expired in December of 2017
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments for the fiscal first quarter of 2018: (Dollars in Millions) December 31, 2017 April 1, 2018 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 751 (27 ) 7 731 731 Equity Investments without readily determinable value $ 510 (20 ) 83 573 573 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of April 1, 2018 and December 31, 2017 were as follows: April 1, 2018 December 31, 2017 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) (8) $ — 351 — 351 342 Interest rate contracts (2)(4) — 3 — 3 7 Total — 354 — 354 349 Liabilities: Forward foreign exchange contracts (7) (9) — 269 — 269 314 Interest rate contracts (3)(4)(7) (10) — 19 — 19 15 Total — 288 — 288 329 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 25 — 25 38 Liabilities: Forward foreign exchange contracts — 53 — 53 38 Other Investments: Equity investments (5) 731 — — 731 751 Debt securities (6) $ — 2,967 — 2,967 5,310 (1) 2017 assets and liabilities are all classified as Level 2 with the exception of equity investments of $751 million , which are classified as Level 1. (2) Includes $2 million and $7 million of non-current other assets for April 1, 2018 and December 31, 2017, respectively. (3) Includes $14 million and $9 million of non-current other liabilities for April 1, 2018 and December 31, 2017, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. The carrying amount of the equity investments were $731 million and $751 million as of April 1, 2018 and December 31, 2017, respectively. (6) Classified as cash equivalents and current marketable securities. (7) Includes collateral exchanged on the credit support agreements on derivatives (8) Forward foreign exchange contracts excluding CSA were $478 million and $418 million for April 1, 2018 and December 31, 2017, respectively. (9) Forward foreign exchange contracts excluding CSA were $364 million and $402 million for April 1, 2018 and December 31, 2017, respectively. (10) Interest rate contracts excluding CSA were $83 million and $165 million for April 1, 2018 and December 31, 2017, respectively.
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of April 1, 2018 comprised: April 1, 2018 (Dollars in Millions) Carrying Amount Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,656 2,656 2,656 Other Sovereign Securities (1) 529 529 529 U.S. Reverse repurchase agreements 2,682 2,682 2,682 Other Reverse repurchase agreements 398 398 398 Corporate debt securities (1) 1,869 1,869 1,864 5 Money market funds 2,944 2,944 2,944 Time deposits (1) 1,159 1,159 1,159 Subtotal 12,237 12,237 12,232 5 Gov't securities 2,705 2,705 2,370 335 Other Sovereign Securities 2 2 — 2 Corporate debt securities 260 260 37 223 Subtotal available for sale debt (2) $ 2,967 2,967 2,407 560 Total cash, cash equivalents and current marketable securities 14,639 565 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities at April 1, 2018 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 2,887 2,887 Due after one year through five years 80 80 Due after five years through ten years — — Total debt securities $ 2,967 2,967
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April 1, 2018 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 2,696 2,696 Non-Current Debt 4.75% Notes due 2019 (1B Euro 1.2323) 1,230 1,330 1.875% Notes due 2019 495 492 3% Zero Coupon Convertible Subordinated Debentures due in 2020 52 92 1.950% Notes due 2020 499 492 2.95% Debentures due 2020 547 553 3.55% Notes due 2021 448 461 2.45% Notes due 2021 349 347 1.65% Notes due 2021 998 973 0.250% Notes due 2022 (1B Euro 1.2323) 1,229 1,236 2.25% Notes due 2022 995 975 6.73% Debentures due 2023 250 298 3.375% Notes due 2023 806 827 2.05% Notes due 2023 498 478 0.650% Notes due 2024 (750MM Euro 1.2323) 920 926 5.50% Notes due 2024 (500 MM GBP 1.4063) 697 865 2.625% Notes due 2025 747 722 2.45% Notes due 2026 1,991 1,877 2.95% Notes due 2027 995 968 2.90% Notes due 2028 1,492 1,443 1.150% Notes due 2028 (750MM Euro 1.2323) 916 923 6.95% Notes due 2029 296 397 4.95% Debentures due 2033 498 580 4.375% Notes due 2033 856 938 1.650% Notes due 2035 (1.5B Euro 1.2323) 1,830 1,907 3.55% Notes due 2036 987 978 5.95% Notes due 2037 991 1,289 3.625% Notes due 2037 1,486 1,479 3.40% Notes due 2038 990 961 5.85% Debentures due 2038 696 908 4.50% Debentures due 2040 538 604 4.85% Notes due 2041 296 340 4.50% Notes due 2043 495 545 3.70% Notes due 2046 1,971 1,966 3.75% Notes due 2047 991 991 3.50% Notes due 2048 742 716 Other 20 20 Total Non-Current Debt $ 29,837 30,897

Pensions and Other Postretireme

Pensions and Other Postretirement Benefits (Tables)	3 Months Ended
	Apr. 01, 2018
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal first quarters of 2018 and 2017 include the following components: Fiscal First Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) April 1, 2018 April 2, 2017 April 1, 2018 April 2, 2017 Service cost $ 309 251 67 61 Interest cost 252 230 37 39 Expected return on plan assets (560 ) (505 ) (2 ) (2 ) Amortization of prior service cost/(credit) 1 — (8 ) (7 ) Recognized actuarial losses 215 152 30 34 Curtailments and settlements (2 ) — — — Net periodic benefit cost $ 215 128 124 125

Accumulated Other Comprehensi26

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Apr. 01, 2018
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 31, 2017 $ (7,351 ) 232 (6,150 ) 70 (13,199 ) Net change 623 — 186 14 823 Cumulative adjustment to retained earnings (232 ) (1) (232 ) April 1, 2018 $ (6,728 ) — (5,964 ) 84 (12,608 ) (1) See Note 1 to the Consolidated Financial Statements for additional details on the adoption of ASU 2016-01

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Apr. 01, 2018
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal first quarters ended April 1, 2018 and April 2, 2017 : Fiscal First Quarters Ended (Shares in Millions) April 1, 2018 April 2, 2017 Basic net earnings per share $ 1.63 1.63 Average shares outstanding — basic 2,682.2 2,706.6 Potential shares exercisable under stock option plans 139.5 141.2 Less: shares which could be repurchased under treasury stock method (90.6 ) (94.6 ) Convertible debt shares 0.8 1.3 Average shares outstanding — diluted 2,731.9 2,754.5 Diluted net earnings per share $ 1.60 1.61

Segments of Business and Geog28

Segments of Business and Geographic Areas (Tables)	3 Months Ended
	Apr. 01, 2018
Segment Reporting [Abstract]
Sales By Segment Of Business	SALES BY SEGMENT OF BUSINESS Fiscal First Quarters Ended (Dollars in Millions) April 1, April 2, Percent Change CONSUMER Baby Care U.S. $ 97 113 (14.2 )% International 360 342 5.3 Worldwide 457 455 0.4 Beauty U.S. 611 567 7.8 International 473 414 14.3 Worldwide 1,084 981 10.5 Oral Care U.S. 157 156 0.6 International 222 206 7.8 Worldwide 379 362 4.7 OTC U.S. 465 477 (2.5 ) International 607 536 13.2 Worldwide 1,072 1,013 5.8 Women's Health U.S. 3 3 0.0 International 240 239 0.4 Worldwide 243 242 0.4 Wound Care/Other U.S. 103 98 5.1 International 60 77 (22.1 ) Worldwide 163 175 (6.9 ) TOTAL CONSUMER U.S. 1,436 1,414 1.6 International 1,962 1,814 8.2 Worldwide 3,398 3,228 5.3 PHARMACEUTICAL Immunology U.S. 2,000 2,123 (5.8 ) International 1,042 807 29.1 Worldwide 3,042 2,930 3.8 REMICADE ® U.S. 916 1,182 (22.5 ) U.S. Exports 142 165 (13.9 ) International 331 325 1.8 Worldwide 1,389 1,672 (16.9 ) SIMPONI / SIMPONI ARIA ® U.S. 224 229 (2.2 ) International 294 199 47.7 Worldwide 518 428 21.0 STELARA ® U.S. 652 547 19.2 International 409 276 48.2 Worldwide 1,061 823 28.9 OTHER IMMUNOLOGY U.S. 66 — * International 8 7 14.3 Worldwide 74 7 * Infectious Diseases U.S. 333 326 2.1 International 497 423 17.5 Worldwide 830 749 10.8 EDURANT ® / rilpivirine U.S. 14 12 16.7 International 196 137 43.1 Worldwide 210 149 40.9 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 273 259 5.4 International 205 171 19.9 Worldwide 478 430 11.2 OTHER INFECTIOUS DISEASES U.S. 46 55 (16.4 ) International 96 115 (16.5 ) Worldwide 142 170 (16.5 ) Neuroscience U.S. 624 664 (6.0 ) International 935 833 12.2 Worldwide 1,559 1,497 4.1 CONCERTA ® / Methylphenidate U.S. 66 108 (38.9 ) International 107 101 5.9 Worldwide 173 209 (17.2 ) INVEGA SUSTENNA ® / XEPLION ® / TRINZA ® / TREVICTA ® U.S. 400 372 7.5 International 296 232 27.6 Worldwide 696 604 15.2 RISPERDAL CONSTA ® U.S. 82 95 (13.7 ) International 114 112 1.8 Worldwide 196 207 (5.3 ) OTHER NEUROSCIENCE U.S. 76 89 (14.6 ) International 418 388 7.7 Worldwide 494 477 3.6 Oncology U.S. 933 664 40.5 International 1,378 930 48.2 Worldwide 2,311 1,594 45.0 DARZALEX ® U.S. 264 201 31.3 International 168 54 * Worldwide 432 255 69.4 IMBRUVICA ® U.S. 227 190 19.5 International 360 219 64.4 Worldwide 587 409 43.5 VELCADE ® U.S. — — — International 313 280 11.8 Worldwide 313 280 11.8 ZYTIGA ® U.S. 407 233 74.7 International 438 290 51.0 Worldwide 845 523 61.6 OTHER ONCOLOGY U.S. 35 40 (12.5 ) International 99 87 13.8 Worldwide 134 127 5.5 Pulmonary Hypertension U.S. 361 — * International 224 — * Worldwide 585 — * OPSUMIT ® U.S. 149 — * International 122 — * Worldwide 271 — * TRACLEER ® U.S. 68 — * International 72 — * Worldwide 140 — * UPTRAVI ® U.S. 124 — * International 16 — * Worldwide 140 — * OTHER U.S. 20 — * International 14 — * Worldwide 34 — * Cardiovascular / Metabolism / Other U.S. 1,103 1,095 0.7 International 414 380 8.9 Worldwide 1,517 1,475 2.8 XARELTO ® U.S. 578 513 12.7 International — — — Worldwide 578 513 12.7 INVOKANA ® / INVOKAMET ® U.S. 204 247 (17.4 ) International 44 37 18.9 Worldwide 248 284 (12.7 ) PROCRIT ® / EPREX ® U.S. 189 169 11.8 International 87 78 11.5 Worldwide 276 247 11.7 OTHER U.S. 132 166 (20.5 ) International 283 265 6.8 Worldwide 415 431 (3.7 ) TOTAL PHARMACEUTICAL U.S. 5,354 4,872 9.9 International 4,490 3,373 33.1 Worldwide 9,844 8,245 19.4 MEDICAL DEVICES Diabetes Care U.S. 117 154 (24.0 ) International 222 245 (9.4 ) Worldwide 339 399 (15.0 ) Diagnostics U.S. — — — International — 1 * Worldwide — 1 * Interventional Solutions U.S. 304 279 9.0 International 336 270 24.4 Worldwide 640 549 16.6 Orthopaedics U.S. 1,307 1,359 (3.8 ) International 943 916 2.9 Worldwide 2,250 2,275 (1.1 ) HIPS U.S. 209 209 0.0 International 154 143 7.7 Worldwide 363 352 3.1 KNEES U.S. 228 246 (7.3 ) International 159 152 4.6 Worldwide 387 398 (2.8 ) TRAUMA U.S. 407 391 4.1 International 289 251 15.1 Worldwide 696 642 8.4 SPINE & OTHER U.S. 463 513 (9.7 ) International 341 370 (7.8 ) Worldwide 804 883 (8.9 ) Surgery U.S. 993 995 (0.2 ) International 1,430 1,276 12.1 Worldwide 2,423 2,271 6.7 ADVANCED U.S. 393 392 0.3 International 573 485 18.1 Worldwide 966 877 10.1 GENERAL U.S. 423 423 0.0 International 704 651 8.1 Worldwide 1,127 1,074 4.9 SPECIALTY U.S. 177 180 (1.7 ) International 153 140 9.3 Worldwide 330 320 3.1 Vision Care U.S. 440 305 44.3 International 675 493 36.9 Worldwide 1,115 798 39.7 CONTACT LENSES / OTHER U.S. 309 256 20.7 International 498 427 16.6 Worldwide 807 683 18.2 SURGICAL U.S. 131 49 * International 177 66 * Worldwide 308 115 * TOTAL MEDICAL DEVICES U.S. 3,161 3,092 2.2 International 3,606 3,201 12.7 Worldwide 6,767 6,293 7.5 WORLDWIDE U.S. 9,951 9,378 6.1 International 10,058 8,388 19.9 Worldwide $ 20,009 17,766 12.6 % *Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business	EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal First Quarters Ended (Dollars in Millions) April 1, April 2, Percent Change Consumer (1) $ 548 596 (8.1 )% Pharmaceutical (2) 3,666 3,663 0.1 Medical Devices (3) 1,579 1,563 1.0 Segment earnings before provision for taxes 5,793 5,822 (0.5 ) Less: Expense not allocated to segments (4) 312 247 Worldwide income before tax $ 5,481 5,575 (1.7 )% (1) Includes amortization expense of $0.1 billion in the fiscal first quarters of 2018 and 2017. (2) Includes acquisition costs related to the Actelion acquisition of $0.1 billion in the fiscal first quarter of 2018. Includes a gain of $0.2 billion in the fiscal first quarter of 2017 related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. Includes amortization expense of $0.8 billion and $0.1 billion in the fiscal first quarters of 2018 and 2017, respectively. (3) Includes a restructuring related charge of $0.1 billion and $0.2 billion in the fiscal first quarters of 2018 and 2017, respectively. Includes amortization expense of $0.3 billion and $0.2 billion in the fiscal first quarters of 2018 and 2017, respectively. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	SALES BY GEOGRAPHIC AREA Fiscal First Quarters Ended (Dollars in Millions) April 1, 2018 April 2, 2017 Percent Change United States $ 9,951 9,378 6.1 % Europe 4,797 3,858 24.3 Western Hemisphere, excluding U.S. 1,567 1,454 7.8 Asia-Pacific, Africa 3,694 3,076 20.1 Total $ 20,009 17,766 12.6 %

Business Combinations and Div29

Business Combinations and Divestitures (Tables)	3 Months Ended
	Apr. 01, 2018
Business Combinations [Abstract]
Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed	The following table presents the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date as well as the adjustments made up to April 1, 2018: (Dollars in Millions) June 16, 2017 April 1, 2018 Cash & Cash equivalents $ 469 469 Inventory (1) 759 759 Accounts Receivable 485 485 Other current assets 93 93 Property, plant and equipment 104 104 Goodwill 5,986 6,161 Intangible assets 25,010 25,010 Deferred Taxes 3 99 Other non-current assets 19 19 Total Assets Acquired 32,928 33,199 Current liabilities 531 956 Deferred Taxes 1,960 1,776 Other non-current liabilities 383 413 Total Liabilities Assumed 2,874 3,145 Net Assets Acquired $ 30,054 30,054 (1) Includes adjustment of $642 million to write-up the acquired inventory to its estimated fair value.
Purchase Price Allocation of Identifiable Intangible Assets	The purchase price allocation to the identifiable intangible assets is as follows: (Dollars in Millions) Intangible assets with definite lives: Patents and trademarks $ 24,230 Total amortizable intangibles 24,230 In-process research and development 780 Total intangible assets $ 25,010
Schedule of Pro Forma Results	The following table provides pro forma results of operations for the fiscal first quarter ended April 2, 2017 as if Actelion had been acquired as of January 4, 2016. The pro forma results include the effect of certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of Actelion. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future. Unaudited Pro forma Consolidated Results (Dollars in Millions Except Per Share Data) April 2, 2017 Net Sales $ 18,410 Net Earnings 4,099 Diluted Net Earnings per Common Share $ 1.49

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Apr. 01, 2018
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated spending under these restructuring programs through the fiscal three months of 2018: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, December 31, 2017 $ 229 — 38 267 Current year activity: Charges — 5 102 107 Cash payments (16 ) — (122 ) (138 ) Settled non cash — (5 ) — (5 ) Accrual adjustment — — — — Reserve balance, April 1, 2018* $ 213 — 18 231 *Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses.

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016	Apr. 01, 2018	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales return reserve (as a percent)	1.00%	1.00%	1.00%
Other assets decrease	$ (4,971)			$ (4,518)
Retained earnings	$ 101,793			$ 104,339
ASU 2016-16 - Income Taxes: Intra-Entity Transfers
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred taxes					$ 2,000
Other assets decrease					700
Retained earnings					1,300
AOCI Attributable to Parent | ASU 2016-01 - Financial Instruments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment					(232)
Retained Earnings | Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment					(47)
Retained Earnings | ASU 2016-01 - Financial Instruments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment					232
Retained Earnings | ASU 2016-16 - Income Taxes: Intra-Entity Transfers
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment					$ 1,311

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Schedule of Impact of Adoption (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Sales to customers	$ 20,009	$ 17,766
Net earnings	4,367	$ 4,422
Assets	156,625		$ 157,303
Liabilities	93,370		97,143
Equity	63,255		$ 60,160
Balance without adoption of ASC 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Sales to customers	19,980
Net earnings	4,342
Assets	156,644
Liabilities	93,367
Equity	63,277
Accounting Standards Update 2014-09 | Effect of change
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Sales to customers	(29)
Net earnings	(25)
Assets	19
Liabilities	(3)
Equity	$ 22

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Schedule of Adjustments for Accounting Standards Update 2017-07 (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of products sold	$ 6,614	$ 5,409
Selling, marketing and administrative expenses	5,263	4,763
Research and development expense	2,404	2,070
Other (income) expense, net	(60)	219
Earnings before provision for taxes on income	$ 5,481	5,575
Accounting Standards Update 2017-07
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of products sold		23
Selling, marketing and administrative expenses		26
Research and development expense		10
Other (income) expense, net		(59)
Earnings before provision for taxes on income		$ 0

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details) - Retained Earnings $ in Millions	Jan. 01, 2018USD ($)
Adjustments for New Accounting Pronouncement
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	$ 1,496
ASU 2014-09 - Revenue from Contracts with Customers
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	(47)
ASU 2016-01 - Financial Instruments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	232
ASU 2016-16 - Income Taxes: Intra-Entity Transfers
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	$ 1,311

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Apr. 01, 2018	Dec. 31, 2017
Summary of Inventories
Raw materials and supplies	$ 1,200	$ 1,140
Goods in process	2,339	2,317
Finished goods	5,475	5,308
Total inventories	9,014	$ 8,765
LifeScan | Discontinued Operations, Held-for-sale or Disposed of by Sale
Summary of Inventories
Assets held for sale, current	$ 100

Intangible Assets and Goodwil36

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Apr. 01, 2018	Dec. 31, 2017
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 10,586	$ 11,283
Total intangible assets - net	52,365	53,228
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	7,113	7,082
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	3,473	4,201
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	35,980	36,427
Less accumulated amortization	7,594	7,223
Finite-Lived Intangible Assets, Net	28,386	29,204
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	21,141	20,204
Less accumulated amortization	7,748	7,463
Finite-Lived Intangible Assets, Net	$ 13,393	$ 12,741

Goodwill By Segment (Details)

Goodwill By Segment (Details) $ in Millions	3 Months Ended
	Apr. 01, 2018USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 31,906
Goodwill, related to acquisitions	53
Goodwill, related to divestitures	0
Currency translation/Other	(810)
Goodwill End of Period	31,149
CONSUMER
Goodwill [Roll Forward]
Goodwill Beginning of Period	8,875
Goodwill, related to acquisitions	0
Goodwill, related to divestitures	0
Currency translation/Other	24
Goodwill End of Period	8,899
PHARMACEUTICAL
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,109
Goodwill, related to acquisitions	0
Goodwill, related to divestitures	0
Currency translation/Other	147
Goodwill End of Period	9,256
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	13,922
Goodwill, related to acquisitions	53
Goodwill, related to divestitures	0
Currency translation/Other	(981)
Goodwill End of Period	$ 12,994

Intangible Assets and Goodwil38

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017	Dec. 31, 2017	Jun. 16, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 4,400
Finite-Lived Intangible Assets, Amortization Expense, Year Two	4,400
Finite-Lived Intangible Assets, Amortization Expense, Year Three	4,400
Finite-Lived Intangible Assets, Amortization Expense, Year Four	4,400
Finite-Lived Intangible Assets, Amortization Expense, Year Five	4,400
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	1,100	$ 300
Goodwill	$ 31,149		$ 31,906
Patents And Trademarks
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	11 years
Customer relationships and other intangible assets
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	22 years
PHARMACEUTICAL
Intangible Assets and Goodwill (Textuals)
Goodwill	$ 9,256		9,109
Medical Devices
Intangible Assets and Goodwill (Textuals)
Goodwill	12,994		$ 13,922
Actelion
Intangible Assets and Goodwill (Textuals)
Goodwill	6,161			$ 5,986
AMO | Medical Devices
Intangible Assets and Goodwill (Textuals)
Total amortizable intangibles		2,300
Goodwill		$ 1,700
Valchlor
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	400
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	600
Patents And Trademarks | LifeScan
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	100
Patents And Trademarks | Valchlor
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	500
Goodwill | LifeScan
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	$ 1,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			24 Months Ended
	Apr. 01, 2018	Apr. 02, 2017	Jan. 01, 2017	Apr. 01, 2018	Jan. 01, 2018	Dec. 31, 2017
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	$ 731			$ 731		$ 751
Foreign currency translation	623	$ 395
Accumulated other comprehensive income on derivatives, after tax	$ 84			$ 84
Reclassification of foreign exchange contracts into earnings, period	next 12 months
Maximum length of time for hedge exposure	18 months
Other income/(expense), net, related to foreign exchange contracts, non hedging	$ (19)	(29)
Unrealized gains on equity investments	$ 0	89
Weighted average interest rate on non-current debt	3.19%			3.19%
Excess of the estimated fair value over the carrying value of debt			$ 2,000
Foreign exchange contracts
Derivative [Line Items]
Collateral Already Posted, Aggregate Fair Value	$ 32			$ 32
Derivative notional amounts outstanding	35,300			35,300		34,500
Cross currency interest rate swaps
Derivative [Line Items]
Derivative notional amounts outstanding	2,300			2,300		2,300
Interest Rate Contract
Derivative [Line Items]
Derivative Liability, Noncurrent	14			14		9
Derivative notional amounts outstanding	1,100			1,100		1,100
Equity Securities
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	731			731		$ 751
Other Comprehensive Income (Loss)
Derivative [Line Items]
Foreign currency translation	(150)			$ (372)
Equity Investments without readily determinable value | Equity Securities
Derivative [Line Items]
Impairment on equity method investments	$ (20)
Equity Investments with readily determinable value | Equity Securities
Derivative [Line Items]
Unrealized gains on equity investments		$ 349
Retained Earnings | ASU 2016-01 - Financial Instruments
Derivative [Line Items]
Cumulative effect adjustment					$ 232

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended		24 Months Ended
	Apr. 01, 2018	Apr. 02, 2017	Apr. 01, 2018	Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax	$ 623	$ 395
Foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Collateral Already Posted, Aggregate Fair Value	32		$ 32
Derivative, Notional Amount	35,300		35,300	$ 34,500
Cross currency interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	2,300		2,300	$ 2,300
Designated as Hedging Instrument
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	(164)	(224)
Gain/ (Loss) reclassified from Accumulated OCI into income	(178)	(179)
Gain/ (Loss) recognized in Other income/expense	17	(11)
Designated as Hedging Instrument | Foreign exchange contracts | Sales to customers
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	31	(13)
Gain/ (Loss) reclassified from Accumulated OCI into income	29	(33)
Gain/ (Loss) recognized in Other income/expense	0	0
Designated as Hedging Instrument | Foreign exchange contracts | Cost of products sold
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	3	(97)
Gain/ (Loss) reclassified from Accumulated OCI into income	2	(31)
Gain/ (Loss) recognized in Other income/expense	12	(17)
Designated as Hedging Instrument | Foreign exchange contracts | Research and development expense
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	(237)	(109)
Gain/ (Loss) reclassified from Accumulated OCI into income	(238)	(102)
Gain/ (Loss) recognized in Other income/expense	0	5
Designated as Hedging Instrument | Foreign exchange contracts | Other (income) expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	(18)	(33)
Gain/ (Loss) reclassified from Accumulated OCI into income	(11)	(35)
Gain/ (Loss) recognized in Other income/expense	5	1
Designated as Hedging Instrument | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	57	28
Gain/ (Loss) reclassified from Accumulated OCI into income	40	22
Gain/ (Loss) recognized in Other income/expense	0	$ 0
Other Comprehensive Income (Loss)
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax	$ (150)		$ (372)

Fair Value Measurements - Sum41

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Dec. 31, 2017
Equity Investment [Roll Forward]
Non Current Other Assets	$ 4,518	$ 4,971
Equity Securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	751
Changes in Fair Value Reflected in Net Income	(27)
Sales/ Purchases/Other	7
Carrying value, end of period	731
Non Current Other Assets	731
Equity Securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	510
Changes in Fair Value Reflected in Net Income	(20)
Sales/ Purchases/Other	83
Carrying value, end of period	573
Non Current Other Assets	$ 573

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	Apr. 01, 2018	Dec. 31, 2017
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 354
Derivatives designated as hedging instruments : Liabilities	288
Available-for-sale Securities, Equity Securities	731	$ 751
Available-for-sale Securities	2,967	5,310
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	731	751
Available-for-sale Securities	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	354	349
Derivatives designated as hedging instruments : Liabilities	288	329
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	2,967
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Interest Rate Contract
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,100	1,100
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	3
Derivatives designated as hedging instruments : Liabilities	19
Derivative Assets, Noncurrent	2	7
Derivative Liabilities, Noncurrent - interest swap	14	9
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	3	7
Derivatives designated as hedging instruments : Liabilities	19	15
Derivative Liability	83	165
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Foreign exchange contracts
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	35,300	34,500
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	351
Derivatives designated as hedging instruments : Liabilities	269
Derivatives not designated as hedging instruments : Assets	25
Derivatives not designated as hedging instruments : Liabilities	53
Foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	351	342
Derivatives designated as hedging instruments : Liabilities	269	314
Derivatives not designated as hedging instruments : Assets	25	38
Derivatives not designated as hedging instruments : Liabilities	53	38
Derivative Asset	478	418
Derivative Liability	364	402
Foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Cross currency interest rate swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,300	2,300
Equity Securities
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities	$ 731	$ 751

Fair Value Measurements - Cash

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Apr. 01, 2018	Dec. 31, 2017	Apr. 02, 2017	Jan. 01, 2017
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 2,967	$ 5,310
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	14,639	17,824	$ 20,909	$ 18,972
Marketable securities	565	$ 472
Held-to-maturity Securities
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	12,237
Held-to-maturity Securities - Estimated Fair Value	12,237
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	12,232
Marketable securities	5
Held-to-maturity Securities | Cash
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	2,656
Held-to-maturity Securities - Estimated Fair Value	2,656
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	2,656
Held-to-maturity Securities | Other Sovereign Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	529
Held-to-maturity Securities - Estimated Fair Value	529
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	529
Marketable securities
Held-to-maturity Securities | U.S. Reverse repurchase agreements
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	2,682
Held-to-maturity Securities - Estimated Fair Value	2,682
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	2,682
Marketable securities
Held-to-maturity Securities | Other Reverse repurchase agreements
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	398
Held-to-maturity Securities - Estimated Fair Value	398
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	398
Held-to-maturity Securities | Corporate debt securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	1,869
Held-to-maturity Securities - Estimated Fair Value	1,869
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	1,864
Marketable securities	5
Held-to-maturity Securities | Money market funds
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	2,944
Held-to-maturity Securities - Estimated Fair Value	2,944
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	2,944
Held-to-maturity Securities | Time deposits(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	1,159
Held-to-maturity Securities - Estimated Fair Value	1,159
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	1,159
Available-for-sale Securities
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	2,967
Available-for-sale Securities - Estimated Fair Value	2,967
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	2,407
Marketable securities	560
Available-for-sale Securities | Other Sovereign Securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	2
Available-for-sale Securities - Estimated Fair Value	2
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	0
Marketable securities	2
Available-for-sale Securities | Corporate debt securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	260
Available-for-sale Securities - Estimated Fair Value	260
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	37
Marketable securities	223
Available-for-sale Securities | US Treasury and Government [Member]
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	2,705
Available-for-sale Securities - Estimated Fair Value	2,705
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	2,370
Marketable securities	$ 335

Fair Value Measurements - Sche

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Apr. 01, 2018USD ($)
Cost Basis
Due within one year	$ 2,887
Due after one year through five years	80
Due after five years through ten years	0
Total debt securities	2,967
Fair Value
Due within one year	2,887
Due after one year through five years	80
Due after five years through ten years	0
Total debt securities	$ 2,967

Fair Value Measurements - Fin45

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($) $ in Millions	Apr. 01, 2018	Dec. 31, 2017
Financial Liabilities
Current Debt	$ 2,696	$ 3,906
Non-Current Debt
Non-Current Debt	29,837	$ 30,675
Carrying Amount
Financial Liabilities
Current Debt	2,696
Non-Current Debt
Non-Current Debt	29,837
Estimated Fair Value
Financial Liabilities
Current Debt	2,696
Non-Current Debt
Non-Current Debt	$ 30,897
4.75% Notes due 2019 (1B Euro 1.2323)
Non-Current Debt
Stated interest rate (as a percent)	4.75%
4.75% Notes due 2019 (1B Euro 1.2323) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,230
4.75% Notes due 2019 (1B Euro 1.2323) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,330
1.875% Notes due 2019
Non-Current Debt
Stated interest rate (as a percent)	1.875%
1.875% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
1.875% Notes due 2019 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 492
3% Zero Coupon Convertible Subordinated Debentures due in 2020
Non-Current Debt
Stated interest rate (as a percent)	3.00%
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 52
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 92
1.950% Notes due 2020
Non-Current Debt
Stated interest rate (as a percent)	1.95%
1.950% Notes due 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 499
1.950% Notes due 2020 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 492
2.95% Debentures due 2020
Non-Current Debt
Stated interest rate (as a percent)	2.95%
2.95% Debentures due 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 547
2.95% Debentures due 2020 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 553
3.55% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 448
3.55% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 461
2.45% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 349
2.45% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 347
1.65% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	1.65%
1.65% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 998
1.65% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 973
0.250% Notes due 2022 (1B Euro 1.2323)
Non-Current Debt
Stated interest rate (as a percent)	0.25%
0.250% Notes due 2022 (1B Euro 1.2323) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,229
0.250% Notes due 2022 (1B Euro 1.2323) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,236
2.25% Notes due 2022
Non-Current Debt
Stated interest rate (as a percent)	2.25%
2.25% Notes due 2022 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 995
2.25% Notes due 2022 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 975
6.73% Debentures due 2023
Non-Current Debt
Stated interest rate (as a percent)	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 250
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 298
3.375% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 806
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 827
2.05% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
2.05% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 478
0.650% Notes due 2024 (750MM Euro 1.2323)
Non-Current Debt
Stated interest rate (as a percent)	0.65%
0.650% Notes due 2024 (750MM Euro 1.2323) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 920
0.650% Notes due 2024 (750MM Euro 1.2323) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 926
5.50% Notes due 2024 (500 MM GBP 1.4063)
Non-Current Debt
Stated interest rate (as a percent)	5.50%
5.50% Notes due 2024 (500 MM GBP 1.4063) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 697
5.50% Notes due 2024 (500 MM GBP 1.4063) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 865
2.625% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	2.625%
2.625% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 747
2.625% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 722
2.45% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,991
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,877
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 995
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 968
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%
2.90% Notes due 2028 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,492
2.90% Notes due 2028 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,443
1.150% Notes due 2028 (750MM Euro 1.2323)
Non-Current Debt
Stated interest rate (as a percent)	1.15%
1.150% Notes due 2028 (750MM Euro 1.2323) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 916
1.150% Notes due 2028 (750MM Euro 1.2323) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 923
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 296
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 397
4.95% Debentures due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 580
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 856
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 938
1.650% Notes due 2035 (1.5B Euro 1.2323)
Non-Current Debt
Stated interest rate (as a percent)	1.65%
1.650% Notes due 2035 (1.5B Euro 1.2323) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,830
1.650% Notes due 2035 (1.5B Euro 1.2323) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,907
3.55% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 987
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 978
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,289
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,486
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,479
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%
3.40% Notes due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 990
3.40% Notes due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 961
5.85% Debentures due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 696
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 908
4.50% Debentures due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 538
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 604
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 296
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 340
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 545
3.70% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,971
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,966
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 991
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%
3.50% Notes due 2048 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 742
3.50% Notes due 2048 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	716
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	20
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 20

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	1 Months Ended	3 Months Ended
	Dec. 31, 2017	Apr. 01, 2018	Apr. 02, 2017
Income Tax (Textuals)
Worldwide effective income tax rate (as a percent)		20.30%	20.70%
Provisional tax cost	$ 13
Effective income tax rate adjustment business combination (as a percent)			3.80%
Effective tax rate adjustment foreign currency exchange rate (as a percent)		1.40%
Excess tax benefit from share based compensation		2.20%	3.60%
Increase to the transition tax on undistributed foreign earnings		$ 0.2
Deferred tax liability foreign earnings		0.3
Deferred tax assets offset		0.1
Unrecognized tax benefits		$ 3.2
Foreign Tax Authority
Income Tax (Textuals)
Change in enacted rate (as a percent)		2.60%
Domestic Tax Authority
Income Tax (Textuals)
Change in enacted rate (as a percent)		0.50%

Pensions and Other Postretire47

Pensions and Other Postretirement Benefits - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 309	$ 251
Interest cost	252	230
Expected return on plan assets	(560)	(505)
Amortization of prior service cost/(credit)	1	0
Recognized actuarial losses	215	152
Curtailments and settlements	(2)	0
Net periodic benefit cost	215	128
Other Benefit Plans
Components of net periodic benefit cost
Service cost	67	61
Interest cost	37	39
Expected return on plan assets	(2)	(2)
Amortization of prior service cost/(credit)	(8)	(7)
Recognized actuarial losses	30	34
Curtailments and settlements	0	0
Net periodic benefit cost	$ 124	$ 125

Pensions and Other Postretire48

Pensions and Other Postretirement Benefit (Details) $ in Millions	3 Months Ended
	Apr. 01, 2018USD ($)
U.S. retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 18
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 9

Accumulated Other Comprehensi49

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 60,160
Net change	823	$ 379
Ending balance	63,255
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(7,351)
Net change	623
Ending balance	(6,728)
Accumulated Net Investment Gain (Loss) Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	232
Net change	0
Cumulative adjustment to retained earnings	(232)
Ending balance	0
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(6,150)
Net change	186
Ending balance	(5,964)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	70
Net change	14
Ending balance	84
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(13,199)
Net change	823
Cumulative adjustment to retained earnings	(232)
Ending balance	$ (12,608)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.63	$ 1.63
Average shares outstanding — basic	2,682,200,000	2,706,600,000
Potential shares exercisable under stock option plans	139,500,000	141,200,000
Less: shares which could be repurchased under treasury stock method	(90,600,000)	(94,600,000)
Convertible debt shares	800,000	1,300,000
Average shares outstanding — diluted	2,731,900,000	2,754,500,000
Diluted net earnings per share	$ 1.60	$ 1.61
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0

Segments of Business and Geog51

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Sales by segment of business
Sales	$ 20,009	$ 17,766
Percent Change (as a percent)	12.60%
U.S.
Sales by segment of business
Sales	$ 9,951	9,378
Percent Change (as a percent)	6.10%
International
Sales by segment of business
Sales	$ 10,058	8,388
Percent Change (as a percent)	19.90%
CONSUMER
Sales by segment of business
Sales	$ 3,398	3,228
Percent Change (as a percent)	5.30%
CONSUMER | U.S.
Sales by segment of business
Sales	$ 1,436	1,414
Percent Change (as a percent)	1.60%
CONSUMER | International
Sales by segment of business
Sales	$ 1,962	1,814
Percent Change (as a percent)	8.20%
CONSUMER | Baby Care
Sales by segment of business
Sales	$ 457	455
Percent Change (as a percent)	0.40%
CONSUMER | Baby Care | U.S.
Sales by segment of business
Sales	$ 97	113
Percent Change (as a percent)	(14.20%)
CONSUMER | Baby Care | International
Sales by segment of business
Sales	$ 360	342
Percent Change (as a percent)	5.30%
CONSUMER | Beauty
Sales by segment of business
Sales	$ 1,084	981
Percent Change (as a percent)	10.50%
CONSUMER | Beauty | U.S.
Sales by segment of business
Sales	$ 611	567
Percent Change (as a percent)	7.80%
CONSUMER | Beauty | International
Sales by segment of business
Sales	$ 473	414
Percent Change (as a percent)	14.30%
CONSUMER | Oral Care
Sales by segment of business
Sales	$ 379	362
Percent Change (as a percent)	4.70%
CONSUMER | Oral Care | U.S.
Sales by segment of business
Sales	$ 157	156
Percent Change (as a percent)	0.60%
CONSUMER | Oral Care | International
Sales by segment of business
Sales	$ 222	206
Percent Change (as a percent)	7.80%
CONSUMER | OTC
Sales by segment of business
Sales	$ 1,072	1,013
Percent Change (as a percent)	5.80%
CONSUMER | OTC | U.S.
Sales by segment of business
Sales	$ 465	477
Percent Change (as a percent)	(2.50%)
CONSUMER | OTC | International
Sales by segment of business
Sales	$ 607	536
Percent Change (as a percent)	13.20%
CONSUMER | Women's Health
Sales by segment of business
Sales	$ 243	242
Percent Change (as a percent)	0.40%
CONSUMER | Women's Health | U.S.
Sales by segment of business
Sales	$ 3	3
Percent Change (as a percent)	0.00%
CONSUMER | Women's Health | International
Sales by segment of business
Sales	$ 240	239
Percent Change (as a percent)	0.40%
CONSUMER | Wound Care/Other
Sales by segment of business
Sales	$ 163	175
Percent Change (as a percent)	(6.90%)
CONSUMER | Wound Care/Other | U.S.
Sales by segment of business
Sales	$ 103	98
Percent Change (as a percent)	5.10%
CONSUMER | Wound Care/Other | International
Sales by segment of business
Sales	$ 60	77
Percent Change (as a percent)	(22.10%)
PHARMACEUTICAL
Sales by segment of business
Sales	$ 9,844	8,245
Percent Change (as a percent)	19.40%
PHARMACEUTICAL | U.S.
Sales by segment of business
Sales	$ 5,354	4,872
Percent Change (as a percent)	9.90%
PHARMACEUTICAL | International
Sales by segment of business
Sales	$ 4,490	3,373
Percent Change (as a percent)	33.10%
PHARMACEUTICAL | Immunology
Sales by segment of business
Sales	$ 3,042	2,930
Percent Change (as a percent)	3.80%
PHARMACEUTICAL | Immunology | U.S.
Sales by segment of business
Sales	$ 2,000	2,123
Percent Change (as a percent)	(5.80%)
PHARMACEUTICAL | Immunology | International
Sales by segment of business
Sales	$ 1,042	807
Percent Change (as a percent)	29.10%
PHARMACEUTICAL | Immunology | REMICADE®
Sales by segment of business
Sales	$ 1,389	1,672
Percent Change (as a percent)	(16.90%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S.
Sales by segment of business
Sales	$ 916	1,182
Percent Change (as a percent)	(22.50%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports
Sales by segment of business
Sales	$ 142	165
Percent Change (as a percent)	(13.90%)
PHARMACEUTICAL | Immunology | REMICADE® | International
Sales by segment of business
Sales	$ 331	325
Percent Change (as a percent)	1.80%
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA®
Sales by segment of business
Sales	$ 518	428
Percent Change (as a percent)	21.00%
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S.
Sales by segment of business
Sales	$ 224	229
Percent Change (as a percent)	(2.20%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International
Sales by segment of business
Sales	$ 294	199
Percent Change (as a percent)	47.70%
PHARMACEUTICAL | Immunology | STELARA®
Sales by segment of business
Sales	$ 1,061	823
Percent Change (as a percent)	28.90%
PHARMACEUTICAL | Immunology | STELARA® | U.S.
Sales by segment of business
Sales	$ 652	547
Percent Change (as a percent)	19.20%
PHARMACEUTICAL | Immunology | STELARA® | International
Sales by segment of business
Sales	$ 409	276
Percent Change (as a percent)	48.20%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY
Sales by segment of business
Sales	$ 74	7
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.
Sales by segment of business
Sales	66	0
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International
Sales by segment of business
Sales	$ 8	7
Percent Change (as a percent)	14.30%
PHARMACEUTICAL | Infectious Diseases
Sales by segment of business
Sales	$ 830	749
Percent Change (as a percent)	10.80%
PHARMACEUTICAL | Infectious Diseases | U.S.
Sales by segment of business
Sales	$ 333	326
Percent Change (as a percent)	2.10%
PHARMACEUTICAL | Infectious Diseases | International
Sales by segment of business
Sales	$ 497	423
Percent Change (as a percent)	17.50%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine
Sales by segment of business
Sales	$ 210	149
Percent Change (as a percent)	40.90%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S.
Sales by segment of business
Sales	$ 14	12
Percent Change (as a percent)	16.70%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International
Sales by segment of business
Sales	$ 196	137
Percent Change (as a percent)	43.10%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
Sales by segment of business
Sales	$ 478	430
Percent Change (as a percent)	11.20%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S.
Sales by segment of business
Sales	$ 273	259
Percent Change (as a percent)	5.40%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International
Sales by segment of business
Sales	$ 205	171
Percent Change (as a percent)	19.90%
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES
Sales by segment of business
Sales	$ 142	170
Percent Change (as a percent)	(16.50%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.
Sales by segment of business
Sales	$ 46	55
Percent Change (as a percent)	(16.40%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International
Sales by segment of business
Sales	$ 96	115
Percent Change (as a percent)	(16.50%)
PHARMACEUTICAL | Neuroscience
Sales by segment of business
Sales	$ 1,559	1,497
Percent Change (as a percent)	4.10%
PHARMACEUTICAL | Neuroscience | U.S.
Sales by segment of business
Sales	$ 624	664
Percent Change (as a percent)	(6.00%)
PHARMACEUTICAL | Neuroscience | International
Sales by segment of business
Sales	$ 935	833
Percent Change (as a percent)	12.20%
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate
Sales by segment of business
Sales	$ 173	209
Percent Change (as a percent)	(17.20%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | U.S.
Sales by segment of business
Sales	$ 66	108
Percent Change (as a percent)	(38.90%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | International
Sales by segment of business
Sales	$ 107	101
Percent Change (as a percent)	5.90%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA®
Sales by segment of business
Sales	$ 696	604
Percent Change (as a percent)	15.20%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® | U.S.
Sales by segment of business
Sales	$ 400	372
Percent Change (as a percent)	7.50%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® | International
Sales by segment of business
Sales	$ 296	232
Percent Change (as a percent)	27.60%
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA®
Sales by segment of business
Sales	$ 196	207
Percent Change (as a percent)	(5.30%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S.
Sales by segment of business
Sales	$ 82	95
Percent Change (as a percent)	(13.70%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International
Sales by segment of business
Sales	$ 114	112
Percent Change (as a percent)	1.80%
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE
Sales by segment of business
Sales	$ 494	477
Percent Change (as a percent)	3.60%
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.
Sales by segment of business
Sales	$ 76	89
Percent Change (as a percent)	(14.60%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International
Sales by segment of business
Sales	$ 418	388
Percent Change (as a percent)	7.70%
PHARMACEUTICAL | Oncology
Sales by segment of business
Sales	$ 2,311	1,594
Percent Change (as a percent)	45.00%
PHARMACEUTICAL | Oncology | U.S.
Sales by segment of business
Sales	$ 933	664
Percent Change (as a percent)	40.50%
PHARMACEUTICAL | Oncology | International
Sales by segment of business
Sales	$ 1,378	930
Percent Change (as a percent)	48.20%
PHARMACEUTICAL | Oncology | DARZALEX®
Sales by segment of business
Sales	$ 432	255
Percent Change (as a percent)	69.40%
PHARMACEUTICAL | Oncology | DARZALEX® | U.S.
Sales by segment of business
Sales	$ 264	201
Percent Change (as a percent)	31.30%
PHARMACEUTICAL | Oncology | DARZALEX® | International
Sales by segment of business
Sales	$ 168	54
PHARMACEUTICAL | Oncology | IMBRUVICA®
Sales by segment of business
Sales	$ 587	409
Percent Change (as a percent)	43.50%
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S.
Sales by segment of business
Sales	$ 227	190
Percent Change (as a percent)	19.50%
PHARMACEUTICAL | Oncology | IMBRUVICA® | International
Sales by segment of business
Sales	$ 360	219
Percent Change (as a percent)	64.40%
PHARMACEUTICAL | Oncology | VELCADE®
Sales by segment of business
Sales	$ 313	280
Percent Change (as a percent)	11.80%
PHARMACEUTICAL | Oncology | VELCADE® | U.S.
Sales by segment of business
Sales	$ 0	0
Percent Change (as a percent)	0.00%
PHARMACEUTICAL | Oncology | VELCADE® | International
Sales by segment of business
Sales	$ 313	280
Percent Change (as a percent)	11.80%
PHARMACEUTICAL | Oncology | ZYTIGA®
Sales by segment of business
Sales	$ 845	523
Percent Change (as a percent)	61.60%
PHARMACEUTICAL | Oncology | ZYTIGA® | U.S.
Sales by segment of business
Sales	$ 407	233
Percent Change (as a percent)	74.70%
PHARMACEUTICAL | Oncology | ZYTIGA® | International
Sales by segment of business
Sales	$ 438	290
Percent Change (as a percent)	51.00%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY
Sales by segment of business
Sales	$ 134	127
Percent Change (as a percent)	5.50%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S.
Sales by segment of business
Sales	$ 35	40
Percent Change (as a percent)	(12.50%)
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International
Sales by segment of business
Sales	$ 99	87
Percent Change (as a percent)	13.80%
PHARMACEUTICAL | Pulmonary Hypertension
Sales by segment of business
Sales	$ 585	0
PHARMACEUTICAL | Pulmonary Hypertension | U.S.
Sales by segment of business
Sales	361	0
PHARMACEUTICAL | Pulmonary Hypertension | International
Sales by segment of business
Sales	224	0
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT®
Sales by segment of business
Sales	271	0
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S.
Sales by segment of business
Sales	149	0
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International
Sales by segment of business
Sales	122	0
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER®
Sales by segment of business
Sales	140	0
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | U.S.
Sales by segment of business
Sales	68	0
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | International
Sales by segment of business
Sales	72	0
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI®
Sales by segment of business
Sales	140	0
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S.
Sales by segment of business
Sales	124	0
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International
Sales by segment of business
Sales	16	0
PHARMACEUTICAL | Pulmonary Hypertension | OTHER
Sales by segment of business
Sales	34	0
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | U.S.
Sales by segment of business
Sales	20	0
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | International
Sales by segment of business
Sales	14	0
PHARMACEUTICAL | Cardiovascular / Metabolism / Other
Sales by segment of business
Sales	$ 1,517	1,475
Percent Change (as a percent)	2.80%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.
Sales by segment of business
Sales	$ 1,103	1,095
Percent Change (as a percent)	0.70%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International
Sales by segment of business
Sales	$ 414	380
Percent Change (as a percent)	8.90%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER
Sales by segment of business
Sales	$ 415	431
Percent Change (as a percent)	(3.70%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | U.S.
Sales by segment of business
Sales	$ 132	166
Percent Change (as a percent)	(20.50%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | International
Sales by segment of business
Sales	$ 283	265
Percent Change (as a percent)	6.80%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO®
Sales by segment of business
Sales	$ 578	513
Percent Change (as a percent)	12.70%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S.
Sales by segment of business
Sales	$ 578	513
Percent Change (as a percent)	12.70%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International
Sales by segment of business
Sales	$ 0	0
Percent Change (as a percent)	0.00%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET®
Sales by segment of business
Sales	$ 248	284
Percent Change (as a percent)	(12.70%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S.
Sales by segment of business
Sales	$ 204	247
Percent Change (as a percent)	(17.40%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International
Sales by segment of business
Sales	$ 44	37
Percent Change (as a percent)	18.90%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX®
Sales by segment of business
Sales	$ 276	247
Percent Change (as a percent)	11.70%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S.
Sales by segment of business
Sales	$ 189	169
Percent Change (as a percent)	11.80%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International
Sales by segment of business
Sales	$ 87	78
Percent Change (as a percent)	11.50%
MEDICAL DEVICES
Sales by segment of business
Sales	$ 6,767	6,293
Percent Change (as a percent)	7.50%
MEDICAL DEVICES | U.S.
Sales by segment of business
Sales	$ 3,161	3,092
Percent Change (as a percent)	2.20%
MEDICAL DEVICES | International
Sales by segment of business
Sales	$ 3,606	3,201
Percent Change (as a percent)	12.70%
MEDICAL DEVICES | Diabetes Care
Sales by segment of business
Sales	$ 339	399
Percent Change (as a percent)	(15.00%)
MEDICAL DEVICES | Diabetes Care | U.S.
Sales by segment of business
Sales	$ 117	154
Percent Change (as a percent)	(24.00%)
MEDICAL DEVICES | Diabetes Care | International
Sales by segment of business
Sales	$ 222	245
Percent Change (as a percent)	(9.40%)
MEDICAL DEVICES | Diagnostics
Sales by segment of business
Sales	$ 0	1
MEDICAL DEVICES | Diagnostics | U.S.
Sales by segment of business
Sales	0	0
MEDICAL DEVICES | Diagnostics | International
Sales by segment of business
Sales	0	1
MEDICAL DEVICES | Interventional Solutions
Sales by segment of business
Sales	$ 640	549
Percent Change (as a percent)	16.60%
MEDICAL DEVICES | Interventional Solutions | U.S.
Sales by segment of business
Sales	$ 304	279
Percent Change (as a percent)	9.00%
MEDICAL DEVICES | Interventional Solutions | International
Sales by segment of business
Sales	$ 336	270
Percent Change (as a percent)	24.40%
MEDICAL DEVICES | Orthopaedics
Sales by segment of business
Sales	$ 2,250	2,275
Percent Change (as a percent)	(1.10%)
MEDICAL DEVICES | Orthopaedics | U.S.
Sales by segment of business
Sales	$ 1,307	1,359
Percent Change (as a percent)	(3.80%)
MEDICAL DEVICES | Orthopaedics | International
Sales by segment of business
Sales	$ 943	916
Percent Change (as a percent)	2.90%
MEDICAL DEVICES | Orthopaedics | HIPS
Sales by segment of business
Sales	$ 363	352
Percent Change (as a percent)	3.10%
MEDICAL DEVICES | Orthopaedics | HIPS | U.S.
Sales by segment of business
Sales	$ 209	209
Percent Change (as a percent)	0.00%
MEDICAL DEVICES | Orthopaedics | HIPS | International
Sales by segment of business
Sales	$ 154	143
Percent Change (as a percent)	7.70%
MEDICAL DEVICES | Orthopaedics | KNEES
Sales by segment of business
Sales	$ 387	398
Percent Change (as a percent)	(2.80%)
MEDICAL DEVICES | Orthopaedics | KNEES | U.S.
Sales by segment of business
Sales	$ 228	246
Percent Change (as a percent)	(7.30%)
MEDICAL DEVICES | Orthopaedics | KNEES | International
Sales by segment of business
Sales	$ 159	152
Percent Change (as a percent)	4.60%
MEDICAL DEVICES | Orthopaedics | TRAUMA
Sales by segment of business
Sales	$ 696	642
Percent Change (as a percent)	8.40%
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S.
Sales by segment of business
Sales	$ 407	391
Percent Change (as a percent)	4.10%
MEDICAL DEVICES | Orthopaedics | TRAUMA | International
Sales by segment of business
Sales	$ 289	251
Percent Change (as a percent)	15.10%
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER
Sales by segment of business
Sales	$ 804	883
Percent Change (as a percent)	(8.90%)
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | U.S.
Sales by segment of business
Sales	$ 463	513
Percent Change (as a percent)	(9.70%)
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | International
Sales by segment of business
Sales	$ 341	370
Percent Change (as a percent)	(7.80%)
MEDICAL DEVICES | Surgery
Sales by segment of business
Sales	$ 2,423	2,271
Percent Change (as a percent)	6.70%
MEDICAL DEVICES | Surgery | U.S.
Sales by segment of business
Sales	$ 993	995
Percent Change (as a percent)	(0.20%)
MEDICAL DEVICES | Surgery | International
Sales by segment of business
Sales	$ 1,430	1,276
Percent Change (as a percent)	12.10%
MEDICAL DEVICES | Surgery | ADVANCED
Sales by segment of business
Sales	$ 966	877
Percent Change (as a percent)	10.10%
MEDICAL DEVICES | Surgery | ADVANCED | U.S.
Sales by segment of business
Sales	$ 393	392
Percent Change (as a percent)	0.30%
MEDICAL DEVICES | Surgery | ADVANCED | International
Sales by segment of business
Sales	$ 573	485
Percent Change (as a percent)	18.10%
MEDICAL DEVICES | Surgery | GENERAL
Sales by segment of business
Sales	$ 1,127	1,074
Percent Change (as a percent)	4.90%
MEDICAL DEVICES | Surgery | GENERAL | U.S.
Sales by segment of business
Sales	$ 423	423
Percent Change (as a percent)	0.00%
MEDICAL DEVICES | Surgery | GENERAL | International
Sales by segment of business
Sales	$ 704	651
Percent Change (as a percent)	8.10%
MEDICAL DEVICES | Surgery | SPECIALTY
Sales by segment of business
Sales	$ 330	320
Percent Change (as a percent)	3.10%
MEDICAL DEVICES | Surgery | SPECIALTY | U.S.
Sales by segment of business
Sales	$ 177	180
Percent Change (as a percent)	(1.70%)
MEDICAL DEVICES | Surgery | SPECIALTY | International
Sales by segment of business
Sales	$ 153	140
Percent Change (as a percent)	9.30%
MEDICAL DEVICES | Vision Care
Sales by segment of business
Sales	$ 1,115	798
Percent Change (as a percent)	39.70%
MEDICAL DEVICES | Vision Care | U.S.
Sales by segment of business
Sales	$ 440	305
Percent Change (as a percent)	44.30%
MEDICAL DEVICES | Vision Care | International
Sales by segment of business
Sales	$ 675	493
Percent Change (as a percent)	36.90%
MEDICAL DEVICES | Vision Care | CONTACT LENSES / OTHER
Sales by segment of business
Sales	$ 807	683
Percent Change (as a percent)	18.20%
MEDICAL DEVICES | Vision Care | CONTACT LENSES / OTHER | U.S.
Sales by segment of business
Sales	$ 309	256
Percent Change (as a percent)	20.70%
MEDICAL DEVICES | Vision Care | CONTACT LENSES / OTHER | International
Sales by segment of business
Sales	$ 498	427
Percent Change (as a percent)	16.60%
MEDICAL DEVICES | Vision Care | SURGICAL
Sales by segment of business
Sales	$ 308	115
MEDICAL DEVICES | Vision Care | SURGICAL | U.S.
Sales by segment of business
Sales	131	49
MEDICAL DEVICES | Vision Care | SURGICAL | International
Sales by segment of business
Sales	$ 177	$ 66

Segments of Business and Geog52

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Segment Reporting Information [Line Items]
Percentage Change in Operating Income Loss	(1.70%)
Restructuring charges	$ 42	$ 85
Medical Devices
Segment Reporting Information [Line Items]
Restructuring charges	100	200
Operating Segments
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 5,793	5,822
Percentage Change in Operating Income Loss	(0.50%)
Operating Segments | CONSUMER
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 548	596
Percentage Change in Operating Income Loss	(8.10%)
Amortization	$ 100	100
Operating Segments | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 3,666	3,663
Percentage Change in Operating Income Loss	0.10%
Amortization	$ 800	100
Gain on sale of equity investments		200
Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 1,579	1,563
Percentage Change in Operating Income Loss	1.00%
Amortization	$ 300	200
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total Segment Operating Income	312	$ 247
Actelion
Segment Reporting Information [Line Items]
Business Combination, Acquisition Related Costs	100
Actelion | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Business Combination, Acquisition Related Costs	$ 100

Segments of Business and Geog53

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Sales by geographic area
Sales	$ 20,009	$ 17,766
Percentage Change In Sales By Geographic Area	12.60%
United States
Sales by geographic area
Sales	$ 9,951	9,378
Percentage Change In Sales By Geographic Area	6.10%
Europe
Sales by geographic area
Sales	$ 4,797	3,858
Percentage Change In Sales By Geographic Area	24.30%
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,567	1,454
Percentage Change In Sales By Geographic Area	7.80%
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,694	$ 3,076
Percentage Change In Sales By Geographic Area	20.10%

Business Combinations and Div54

Business Combinations and Divestitures (Details) - USD ($)	Jun. 16, 2017	Apr. 01, 2018	Apr. 02, 2017	Oct. 01, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Proceeds from Sale of Productive Assets		$ 20,000,000	$ 31,000,000
Goodwill		31,149,000,000			$ 31,906,000,000
Payments to acquire businesses		82,000,000	4,852,000,000
Asset write-downs		0	$ 37,000,000
Medical Devices
Business Acquisition [Line Items]
Goodwill		12,994,000,000			$ 13,922,000,000
Patents And Trademarks
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent		600,000,000
Actelion
Business Acquisition [Line Items]
Goodwill, Subsequent Recognition of Deferred Tax Asset				$ 200,000,000
Business Combination, Initial Accounting Incomplete, Adjustment, Current Liabilities				$ 400,000,000
Goodwill	$ 5,986,000,000	6,161,000,000
Business Acquisition, Share Price	$ 280
Payments to acquire businesses	$ 29,600,000,000
Weighted average useful life	9 years
Business Combination, Acquisition Related Costs		100,000,000
Actelion | Minimum
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 years
Actelion | Maximum
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Actelion | In-process research and development
Business Acquisition [Line Items]
Fair Value Inputs, Discount Rate	9.00%
Idorsia
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	9.90%
Convertible Note, Equity Interest, Percentage	22.10%
Idorsia | Convertible Debt
Business Acquisition [Line Items]
Long-term Debt	$ 500,000,000
Debt Instrument, Term	10 years
Idorsia | Line of Credit
Business Acquisition [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 250,000,000
Idorsia | Debt Instrument, Redemption, Period One | Convertible Debt
Business Acquisition [Line Items]
Convertible Note, Equity Interest, Percentage	16.00%
Debt Instrument, Restrictive Covenants, Shareholder Ownership Threshold, Percent	20.00%
AMO
Business Acquisition [Line Items]
Weighted average useful life			14 years 4 months 24 days
AMO | Medical Devices
Business Acquisition [Line Items]
Goodwill			$ 1,700,000,000
Payments to acquire businesses			4,300,000,000
Total amortizable intangibles			$ 2,300,000,000
Discontinued Operations, Held-for-sale or Disposed of by Sale | LifeScan
Business Acquisition [Line Items]
Disposal group consideration		2,100,000,000
Disposal group inventory		100,000,000
Disposal group property, plant and equipment		200,000,000
Disposal group intangible assets		100,000,000
Disposal group goodwill		1,000,000,000
Assets held for sale, current		100,000,000
Valchlor
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent		400,000,000
Valchlor | Patents And Trademarks
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent		$ 500,000,000

Business Combinations and Div55

Business Combinations and Divestitures - Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jun. 16, 2017	Apr. 01, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill		$ 31,149	$ 31,906
Actelion
Business Acquisition [Line Items]
Cash & Cash equivalents	$ 469	469
Inventory	759	759
Accounts Receivable	485	485
Other current assets	93	93
Property, plant and equipment	104	104
Goodwill	5,986	6,161
Intangible assets	25,010	25,010
Deferred Taxes	3	99
Other non-current assets	19	19
Total Assets Acquired	32,928	33,199
Current liabilities	531	956
Deferred Taxes	1,960	1,776
Other non-current liabilities	383	413
Total Liabilities Assumed	2,874	3,145
Net Assets Acquired	30,054	$ 30,054
Inventory write up	$ 642

Business Combinations and Div56

Business Combinations and Divestitures - Purchase Price Allocation of Identifiable Intangible Assets (Details) - Actelion $ in Millions	Jun. 16, 2017USD ($)
Business Acquisition [Line Items]
Total intangible assets	$ 25,010
In-process research and development
Business Acquisition [Line Items]
Indefinite-lived Intangible Assets Acquired	780
Patents and trademarks
Business Acquisition [Line Items]
Total amortizable intangibles	$ 24,230

Business Combinations and Div57

Business Combinations and Divestitures - Schedule of Pro Forma Results (Details) - Actelion $ / shares in Units, $ in Millions	3 Months Ended
	Apr. 02, 2017USD ($)$ / shares
Business Acquisition [Line Items]
Net Sales	$ 18,410
Net Earnings	$ 4,099
Diluted Net Earnings per Common Share | $ / shares	$ 1.49

Legal Proceedings (Details)

Legal Proceedings (Details)	Apr. 01, 2018patientclaimant
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	2,000
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	10,200
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	54,000
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	14,000
XARELTO®
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	26,300
Talc
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	9,100
Invokana
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	1,100
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement | patient	10,000

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) $ in Millions	3 Months Ended
	Apr. 01, 2018USD ($)Employee	Apr. 02, 2017USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 42	$ 85
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	107
Restructuring charges recorded to date	$ 2,100
Number of positions eliminated | Employee	2,500
Number of positions eliminated and receiving severance | Employee	1,800
Medical Devices | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 6
Medical Devices | Other Income Expense Net
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 59
Medical Devices | Minimum
Restructuring Cost and Reserve [Line Items]
Positions eliminated (as a percent)	5.00%
Medical Devices | Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	$ 2,400
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	100	$ 200
Medical Devices | Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	1,900
Cost savings expected	$ 600
Period for activity	4 years
Medical Devices | Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	$ 2,300
Cost savings expected	$ 800
Period for activity	5 years
Estimated cost settled with cash (as a percent)	70.00%

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2018	Apr. 02, 2017
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 42	$ 85
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning	267
Restructuring charges	107
Payments for Restructuring	(138)
Restructuring Reserve, Settled without Cash	(5)
Restructuring Reserve, Accrual Adjustment	0
Reserve balance ending	231
Medical Devices | Employee Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning	229
Restructuring charges	0
Payments for Restructuring	(16)
Restructuring Reserve, Settled without Cash	0
Restructuring Reserve, Accrual Adjustment	0
Reserve balance ending	213
Medical Devices | Asset Write-off
Restructuring Reserve [Roll Forward]
Reserve balance beginning	0
Restructuring charges	5
Payments for Restructuring	0
Restructuring Reserve, Settled without Cash	(5)
Restructuring Reserve, Accrual Adjustment	0
Reserve balance ending	0
Medical Devices | Other Restructuring
Restructuring Reserve [Roll Forward]
Reserve balance beginning	38
Restructuring charges	102
Payments for Restructuring	(122)
Restructuring Reserve, Settled without Cash	0
Restructuring Reserve, Accrual Adjustment	0
Reserve balance ending	$ 18